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ERIC RICHARD BUCK. Role of protein kinase phosphorylation on SERT 
oligomerization: a novel mechanistic view. (Under the direction of SAMMANDA 
RAMAMOORTHY). 
The serotonin transporter (SERT) is the primary mechanism for the termination of 
synaptic signaling. It is of clinical relevance because it is a high-affinity target for 
therapeutics such as anti-depressants (SSRIs) and drugs of abuse such as cocaine, 
amphetamine, and 3,4 methylenedioxymethamphetamine (ecstasy). It is also seen as a 
protein potentially involved in the etiology underlying disorders such as clinical 
depression, autism, anxiety-related disorders, obsessive compulsive disorder, and 
anorexia nervosa among others. SERT has also been found to be a target of protein 
kinases that exert their effects through phosphorylation. For example, activation of 
protein kinase C (PKC) decreases SERT uptake of serotonin (5-HT) by increasing 
internalization of SERT from the plasma membrane. Conversely, phosphorylation of 
SERT by protein kinase G (PKG) appears to increase SERT uptake of 5-HT from the 
synapse. It has also been thought that oligomerization of SERT is a necessary component 
of endoplasmic reticulum (ER) exocytosis and plasma membrane expression. However, 
there has been no common tie between these two very important processes of SERT 
regulation. In this study, we examined regulation of SERT phosphorylation's effect on 
SERT oligomerization. 
Our results indicated that phosphorylation of SERT by kinases that stimulate 5-
HT uptake, p38 mitogen-activated protein kinase (MAPK) and PKG decrease SERT 
oligomerization in HEK-293 cells. We also identified the putative phosphorylation site 
xi 
ofSERT for PKG. PKC however showed the opposite effect by increasing SERT 
oligomerization upon activation with phorbol esters. In this study we also show that 
phosphorylation is a potential mechanism for regulating the oligomeric state of SERT 
using site-directed mutagenesis at a putative site in SERT phosphorylated by PKG. 
Lastly, we show that human mutant polymorphisms found in patients with obsessive-
compulsive disorder and other serotonin-related disorders, that have been shown to 
increase 5-HT uptake by SERT, appear to decrease the homo-oligomeric complex of 
SERT much like PKG and p38 MAPK. Lastly, we show that oligomerization is 
necessary for correct protein expression and that physiologically relevant concentrations 
of cocaine appear to increase SER T oligomerization. These results show for the first 
time that the oligomerization status of SERT can be regulated by protein kinases. 
xii 
Chapter I. GENERAL INTRODUCTION 
1.1. Properties and Identification of Monoamine Transporters 
Effective neuronal communication in the brain requires precIse and dynamic 
regulation of neurotransmitter concentrations. The monoamines, dopamine (DA), 
norepinephrine (NE), and serotonin (5-HT), act as neurotransmitters in peripheral and 
central nervous (PNS and eNS) in a variety of physiological (cognitive, autonomic, 
reward-reinforced learning; and emotional) functions (Bunney, Sesace et al. 1987; Nicoll, 
Madison et al. 1987; Fozzard 1989; Jacobs and Fornal 1991; Jacobs and Azmitia 1992; 
Goldstein 1995) At the molecular level, monoamine signaling is dynamically regulated 
by a diverse set of macromolecules including biosynthetic enzymes, secretory proteins, 
ion channels, pre- and post-synaptic receptors, and transporters. 
Structure, Function, and Pharmacology of Monoamine Transporters 
The uptake of DA, 5-HT, and NE following release into the nerve terminals 
through monoamine transporters is the principal process for termination of respective 
monoaminergic (dopamanergic, serotonergic, and noradrenergic) neurotransmission. The 
high-affinity plasma membrane dopamine transporter (DAT), norepinephrine transporter 
(NET), and serotonin transporter (SER T) dictate the concentration, duration, and 
magnitude of postsynaptic responses. Several different types of cell-surface receptors 
exist to confer the specific actions of DA, 5-HT, and NE on target cells (Glennon and 
Dukat 1995). However, the extracellular clearance of DA, 5-HT, and NE is carried out 
by only one form (Ramamoorthy, Bauman et al. 1993) of DAT, SERT, or NET, 
respectively, in the brain and periphery (Blakely, Berson et al. 1991; Hoffman, Mezey et 
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al. 1991; Lesch, Wolozin et al. 1993). Monoamine transporters belong to the Na + fer -
dependent gene family. The amino acid sequence predicts the presence of 12 
hydrophobic transmembrane domains with cytoplasmic NH2 and eOOH termini. Also, 
the amino acid sequence reveals several potential phosphorylation sites for multiple 
kinases in the cytoplasmic domains (Ramamoorthy, Bauman et al. 1993). The 
translocation ofamines by amine transporter requires Na+ and cr in the external medium. 
Monoamine transporters are the high-affinity targets for various therapeutic agents and 
substances of abuse (Ramamoorthy, Bauman et al. 1993). The critical role of monoamine 
transporters for normal brain function is underscored by the wide range of drugs that 
target monoamine transporters, including medications for depression, attention deficit 
hyperactivity disorder (ADHD), smoking, addiction, obsessive-compulsive disorder, and 
sleep disorders. The majority of these drugs interfere with the transporter-mediated 
clearance of extracellular biogenic amine neurotransmitters. An ensuing surge of 
extracellular monoamines activates monoamine receptors and triggers a cascade of 
molecular and cellular events to produce therapeutic benefit. 
1.1.1 The serotonin transporter 
The monoamine transporter serotonin (5-hyrdoxytraptamine, 5-HT) plays an 
important role as a neuromodulator in adult central and peripheral nervous system 
regulating a variety of different physiological processes including mood, sleep, sexual 
drive, appetite, memory, thyroid function, gastrointestinal motility, vasoconstriction, and 
addiction (Fozzard 1989; Jacobs and Azmitia 1992). The uptake of synaptic 5-HT 
through Na-fCr -dependent SERT is the principal process of terminating serotonergic 
neurotransmission. Though more than 15 different types of cell-surface receptors exist to 
.; . 
3 
confer the specific actions of 5-HT on target cells (Glennon and Dukat 1995), a single 
gene (Ramamoorthy, Bauman et al. 1993) encoding SER T appears to be responsible for 
extracellular 5-HT clearance in the brain and periphery, SERT is mapped to human 
chromosome band 1 7 q 11.1-q 12 (Blakely, Berson et al. 1991; Hoffman, Mezey et al. 
1991; Lesch, Wolozin et al. 1993). In addition to serotonergic neurons, SERTs are also 
expressed in platelets (Rudnick 1977; Lesch, Wolozin et al. 1993), placenta (Balkovetz, 
Tiruppathi et al. 1989), intestinal crypt epithelia (Wade, Chen et al. 1996), adrenal 
chromaffin cells (Tecott, Shirom et al. 1995; Schroeter, Levey et al. 1997), mast cells 
(Hoffman, Mezey et al. 1991; Miller and Hoffman 1994), medullary thyroid carcinoma 
cells (Clark, Lanigan et al. 1995), thyroid follicular cells (Tamir, Hsiung et al. 1996), and 
lymphocytes (Lesch, Bengel et al. 1996; Faraj, Olkowski et al. 1997). While clearance of 
synaptic extrasynaptic 5-HT appears to be the principal function of SERTs, certain cells, 
notably platelets, utilize SERTS to acquire 5-HT from the extracellular environment for 
subsequent release, involved in the process of platelet activation (Cirillo, Golino et al. 
1999; Musselman, Marzec et al. 2002). Platelets and 5-HT neurons share many common 
properties, including vesicular monoamine transporters (VMATs), 5-HT release, 
biochemistry, identical SERT sequences, and 5-HT receptors (Owens and Nemeroff 
1994). Therefore, platelets have been widely used as a peripheral indicator of central 5-
HT metabolism and SER T function in psychiatric disorders and vascular diseases in 
which 5-HT has been implicated (Meltzer, Arora et al. 1981; Wirz-Justice 1988). In the 
lung, SERTs efficiently clear plasma-borne 5-HT and regulate blood 5-HT levels with the 
help of platelets. 
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Altered serotonergic neurotransmission and 5-HT have long been associated with 
psychiatric disorders, including depression, suicide, impulsive violence, and alcoholism 
(Heinz, Mann et al. 2001; Hahn and Blakely 2002a). Reduced binding of SERT ligands 
imipramine and paroxetine to brain and platelet SERTs in patients with depression and 
suicide victims indicated that altered SERT function might contribute to aberrant 
behaviors. All SERT antagonists have been shown to be effective antidepressants. 
Drugs that block SERT, including tricyclic antidepressants such as imipramine, and 
selective serotonin reuptake inhibitors (SSRls) like fluoxetine (Prozac), paroxetine 
(Paxil), sertraline (Zoloft), and citalopram (Celexa) are successfully used in the treatment 
of depression. SSRls rapidly inhibit the uptake of 5-HT. However, the therapeutic 
efficacy of antidepressants develops slowly during several weeks of continuous 
treatment. The therapeutic efficacies of antidepressant drugs have been realized for 
years, however, current knowledge regarding their mechanisms of action remains 
incomplete. Because it has been well recognized that treatment response to 
antidepressants generally requires two or more weeks, studies on long-term adaptive 
changes have been focused on regulation of receptors, transcription factors, and kinases. 
SERT antagonists, including antidepressants and cocaine, limit clearance of neuronally 
released 5-HT signaling, and hence neural plasticity. Therefore, changes in SERT 
kinetics and number will strongly influence the efficacy of antidepressants in the 
treatment of depression. 
Receptors that are known to influence amIne transporter function have been 
implicated in depression as well as in animal models (Langer 1987; Stockmeier, Shapiro 
et al. 1998; Maes, Van Gastel et al. 1999; Murphy, Wichems et al. 1999; Stockmeier, Shi 
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et al. 2002). Altered receptor expression, sensitivity to receptor ligands, and changes in 
downstream signaling cascades have been demonstrated in antidepressant drug-treated 
animals. Chronic antidepressant administrations alter activity and expression of second 
messenger-regulated protein kinases such as protein kinase C (PKC), 
calcium/calmodulin-dependent kinase II (CamKII), protein kinase A (PKA) , mitogen-
activated protein kinase (MAPK) as well as expression of cAMP-specific 
phosphodiesterase 4A and 4B isoforms and CREB protein (Popoli, Vocaturo et al. 1995; 
Popoli, Venegoni et al. 1997; Tadokoro, Kiuchi et al. 1998; Battersby, Ogilvie et al. 
1999; Takahashi, Terwilliger et al. 1999; Consogno, Dorigo et al. 2000; Popoli, Brunello 
et al. 2000). These neuronal adaptations could serve as molecular switches for amine 
clearance in vivo by changing the degree of receptor sensitivity, and thus signals linked 
to SERT regulation. Some examples below describe how receptor-linked regulation of 
SER T may playa role in depression and antidepressant treatments and vice versa. 
Presynaptic inhibitory u2-adrenoreceptors are located on serotonergic nerve 
endings, and endogenous NE is able to control the release and uptake of 5-HT (Ansah, 
Ramamoorthy et al. 2000). Decreased platelet u2-adrenoreceptor density and 
dysregulation of nerve terminal u2-adrenoreceptor density and sensitivity have been 
shown in depressed patients (Maes, Van Gastel et al. 1999). Genetic deletion of the U2-
adrenoreceptor in mice renders animals to mimic depression, suggesting a role for U2-
adrenoreceptor in the modulation of depression and anxiety (Schramm, McDonald et al. 
2001). Receptors for u2-adrenoreceptor, adenosine, histamine, and 5-HT also regulate 5-
HT uptake (Launay, Bondoux et al. 1994; Miller and Hoffman 1994; Ansah, 
Ramamoorthy et al. 2000). Chronic antidepressant treatment increases expression of 
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brain-derived growth factor (BDNF), BDNF receptors, and TrkB receptor (the receptor 
target of BDNF) function (Morinobu, Nibuya et al. 1995; Nibuya, Morinobu et al. 1995; 
Russo-Neustadt, Beard et al. 2000). BDNF produces antidepressant-like behavioral 
effects and increases serotonergic neurotransmission (Celada, Siuciak et al. 1996; Altar 
1999; Shirayama, Chen et al. 2002). BDNF, but not nerve growth factor (NGF), has been 
shown to regulate SER T expression in B lymphocytes, suggesting the role of BDNF in 
functional SERT expression (Mossner, Daniel et al. 2000). Evidence shows that BDNF 
and activation of TrkB receptors increases 5-HT clearance by increasing SERT activity in 
the rat hippocampus (Daws, Gerhardt et al. 1999; Daws, Gould et al. 2000). Mice 
lacking SERT have altered expression and function of 5-HT1a and 5-HTlb receptors 
(Fabre, Beaufour et al. 2000). On the other hand, mice lacking the 5-HT1a and 5-HT1b 
receptors show altered expression of SERT (Ase, Reader et al. 2001). Thus, elevated 
extraneuronal 5-HT could influence 5-HT1a and 5-HT1b receptor signals, and hence 
SERT activity. Substance P (SP) and substance Preceptor (NK-l) have been implicated 
in the pathophysiology of depression (Rupniak and Kramer 1999; Lieb, Ahlvers et al. 
2002). Furthermore, genetic deletion and pharmacological blockade of NKI receptor 
decrease depressive behaviors and increase serotonergic activity (Rupniak, Carlson et al. 
2001; Bilkei-Gorzo, Racz et al. 2002), suggesting the serotonergic system as a potential 
target for effects of SP on depression-related behaviors (Haddjeri and Blier 2001; 
Rupniak, Carlson et al. 2001; Santarelli, Gobbi et al. 2001). Reduction of SP in the rat 
brain after chronic antidepressant treatment (Shirayama, Mitsushio et al. 1996; 
Shirayama, Chen et al. 2002) raises the possibility that the degree of NKI receptor 
regulating SERT function may be altered after chronic exposure to antidepressants. 
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1.1.2 The Norepinephrine Transporter 
The noradrenergic system modulates attention, alertness, arousal, and vigilance. 
Noradrenergic signaling is intimately linked with behavioral arousal (Astier, Van 
Bockstaele et al. 1990) and is affected in stress-related paradigms linked to depression 
(Pavcovich, Cancela et al. 1990). NE is an important chemical messenger in the nervous 
system and regulates affective states, learning and memory, and endocrine and autonomic 
functions. It has been implicated in depression, aggression, addiction, and cardiac and 
thermal regulation. NE acutely inhibits nociceptive transmission mediated by substance 
P (NK-lr), potentiates opioid analgesia, and underlies part of the antinociceptive effects 
of tricyclic antidepressants and psycho stimulants (Holden and N aleway 2001; Jasmin, 
Tien et al. 2002). NET regulates noradrenergic signaling in the CNS and PNS by 
mediating the clearance of NE and is an important target for antidepressants and 
psycho stimulants (Axelrod and Kopin 1969; Iversen 1978; Pacholczyk, Blakely et al. 
1991; Amara and Arriza 1993). The importance of NET to NE homeostasis suggests a 
role for NET in disorders of both central and autonomic nervous systems. Involvement 
of noradrenergic systems in mood disorders is suggested by the evidence that depression 
is accompanied by altered indices of noradrenergic function and that effective 
antidepressants enhance extracellular NE levels (Ressler and Nemeroff 1999; Ressler and 
Nemeroff 2001). Furthermore, NET-binding sites are decreased in brains of patients with 
major depression (Klimek, Stockrneier et al. 1997). The activation and sensitization of 
NE systems in response to stress suggest that NE may play a role in disorders triggered 
by early life trauma, including depression and Post-Traumatic Stress Disorder (PTSD) 
(Heim and Nemeroff 2001). NE also plays an important role in attention, learning and 
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memory, and is hypothesized to contribute to ADHD (Biederman and Spencer 1999). 
Stimulant drugs used to treat ADHD act on both the NET and the DAT, and atomoxetine, 
which selectively targets NET, is also effective in treating ADHD. The activity of NET 
at postganglionic sympathetic nerve terminals, especially in the heart, is impacted in 
diseases of the cardiovascular system (Blakely 2001; Robertson, Flattem et al. 2001). 
Diminished NE uptake sites and activity have been observed in hypertension, diabetes, 
cardiomyopathy, and heart failure. Ischemia-induced efflux of nonvesicular, cytoplasmic 
NE via NET may also contribute to fatal arrhythmias (Hahn and Blakely 2002b). NETs 
are also expressed in peripheral tissues such as adrenal glands, vas deferens, and placenta. 
NET is the only catecholamine transporter present in the placenta and is thought to shield 
the fetus from fluctuating catecholamine levels in the maternal circulation. Analogous to 
the brain, blockade of placental NET by cocaine may result in elevated catecholamines in 
the maternal circulation. It is likely that pregnancy complications such as pre-term birth, 
spontaneous abortion, and abruption placenta association with maternal cocaine abuse 
relate to changes in the placental vascular physiology resulting from altered 
catecholamine signaling. DA affinity for NET is higher compared with its affinity for 
OAT, and NET density in the prefrontal cortex of the brain is higher than DAT density 
(Hom 1973; Giros, Wang et al. 1994; Eshleman, Carmolli et al. 1999; Moron, 
Brockington et al. 2002). NET -knockout (KlO) mice do not effectively clear DA in the 
frontal cortex, underscoring the NET as a DA carrier in this brain region (Moron, 
Brockington et al. 2002), and amphetamine reportedly releases DA from noradrenergic 
neurons in the prefrontal cortex. NET is poorly expressed in the striatum and robustly 
expressed in the frontal cortex (Shoblock, Maisonneuve et al. 2004). Thus, DA T /NET 
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ratios in discrete brain regions are likely to govern selective catecholamine transport as 
well as selective drug effects on catecholamine transport. The behavioral outcome 
depends on the test used. In studies on locomotion in NET KlO mice, it has been 
suggested (Mead, Rocha et al. 2002) that differences in baseline locomotion should be 
taken into account interpreting the observed psychostimulant supersensitivity (Xu, 
Gainetdinov et al. 2000) and reduced cocaine sensitivity (Mead, Rocha et al. 2002). 
While these studies indicate a role for the NET in the acute drug effect, the NET is not a 
prerequisite for the locomotor effect as opposed to the DA T that is critical as shown by 
the lack of effect of cocaine or amphetamine in DAT KID mice (Giros, Jaber et al. 1996; 
Mead, Rocha et al. 2002). In contrast, in cocaine self-administration studies, likely 
measuring cocaine's reinforcing effect~ NET becomes a major contributor in the absence 
of DAT. Thus, while cocaine self-administration in DAT KJO mice is intact (Rocha, 
Faumagalli et al. 1998), DA is cleared by NET in DA T KlO animals (Moron, 
Brockington et al. 2002). In support of this notion, cocaine and amphetamine increased 
dialysate DA in the nucleus accumbens of DA T KlO mice as did the specific NET 
blocker reboxetine; selective blockade of DAT by GRR 12909 in DAT KlOx had no 
effect on nucleus accumbens DA (Carboni, Spielewoy et al. 2001). It appears therefore 
that cocaine or amphetamine can act on NET, which takes over the clearance of DA in 
the nucleus accumbens when DA T is absent in DA T KlOx. However, more infonnation 
is needed to fully understand the mechanism as desipramine did not enhance DA uptake 
measured in vitro by voltammetry in the nucleus accumbens of DA T KlOs (Budygin, 
John et al. 2002). 
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1.1.3 The Dopamine Transporter 
DA signaling regulates many critical functions such as movement, emotion, and 
cognition (Carlsson, Waters et al. 2001; Greengard 2001). DAT terminates dopaminergic 
neurotransmission by re-uptake of DA in presynatpic neurons and plays a key role in DA 
recycling. DA T can also provide reverse transport of DA under certain circumstances. 
Psycho stimulants such as cocaine and amphetamine are drugs used for ADHD such as 
methylphenidate exert their actions via DAT (Sulzer, Chen et al. 1995; Sora, Wichems et 
al. 1998). Recent molecular and pharmacological analyses using monoamine transporter-
KID mice have confirmed the physiological importance and requirement of presynatpic 
amine transporter expression for normal transmitter clearance, presynaptic transmitter 
homeostasis, postsynaptic, and drug responses (Rioux, Fabre et al. 1999; Xu, Gainetdinov 
et al. 2000; Carboni, Spielewoy et al. 2001). In particular, functional loss of DA T either 
through pharmacological inhibition (Kula and Baldessarini 1991; Giros, EI Mestikawy et 
al. 1992) or through gene knockout ( Giros, Jaber et al. 1996) results in profound physical, 
physiological, and behavioral changes. 
DA T not only functions as a carrier for DA but also mediates other processes, 
adding another level of complexity to its potential role in neuropsychiatric diseases. In 
the substantia nigra, DA T can regulate DA release, previously thought to be the domain 
of D2 DA autoreceptors. Originally discovered in DAT -expressing cells, DA T produces 
at least three types of ion channel-like conductances (Sonders, Zhu et al. 1997; Ingram, 
Prasad et al. 2002). In the substantia nigra, substrate transport by the DAT initiates an 
excitatory DAT -mediated current, cell depolarization, and consequent augmentation of 
somatodendritic DA release (Falkenburger, Barstow et al. 2001; Ingram, Prasad et al. 
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2002). DAT -mediated regulation of DA release differs from the O2 autoreceptor control 
of release. In the presence of DA, DA T promotes DA release, whereas D2 autoreceptor 
attenuates release. DA T -mediated DA release is triggered at relatively low OA levels, 
whereas D2 autoreceptors control of DA release requires significantly higher DA 
concentrations (Ingram, Prasad et al. 2002). Finally, DAT substrate clearance (and 
associated ion conductances) results in OA-neuron depolarizations and increased 
neuronal firing rate, even if 02 receptor are blocked (Mortensen and Amara 2003). DAT 
control of DA release is region specific. In the striatum, DA clearance is a primary 
function of the DA T, whereas in the substantia nigra the DAT regulates extracellular DA 
levels by controlling both clearance and release. In DA terminal regions, D2-receptor 
activation has been reported to enhance OAT function, adding another autoreceptor-
mediated mechanism in regulating extraneuronal DA levels (Wu, Reith et al. 2002; 
Gulley and Zanheiser 2003). Evidence for the critical and brain region-specific role of 
the DA T in regulating DA neurotransmission and presynaptic homeostasis comes from 
targeted deletion of the DAT gene in mice. In comparison with wild-type controls, DAT 
mutant mice exhibit significant phenotypic transformations, including hyperactivity, 
small size, skeletal abnormalities, pituitary hypoplasia, impaired care by females for their 
offspring, cognitive and sensorimotor gating deficits, and sleep dysregulation. The 
striatum of the mutant mice adapts by reducing the DA-synthesizing enzyme tyrosine 
hydroxylase, vesicular DA stores, stimulated DA release and Dl and D2 (but not D3) 
receptor densities and function [for review, see (Gainetdinov and Caron 2003)]. The 
extreme changes in DA-signaling systems of the striatum are not replicated in the frontal 
cortex, and indeed, this brain region retains normal dopaminergic systems. Because DA T 
l 
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density in the frontal cortex is low as DA uptake proceeds normally in the frontal cortex 
DAT-KiO mice, it is unlikely that drug-induced blockade of DAT is a significant 
contributor to elevated DA levels in the prefrontal cortex. In the normal brain, the frontal 
cortex expresses much lower levels of the DA T and DA autoreceptors, stores less DA, 
and relies more on DA synthesis than on vesicular recycling for DA release. These 
contrasting cortical and striatal DA regulatory processes have implications for ADHD. 
1.2 Regulation of Monoamine Transporters 
Monoamine Transporters and Their Functional Regulation 
Monoamine transporters in general, function by sequestering monoamines from 
specific nerve terminals. However, in several brain regions and under certain conditions, 
monoamine transporter functions can overlap (Cases, Lebrand et al. 1998; Pan, Gembom 
et al. 2001; Moron, Brockington et al. 2002). Pharmacological and behavioral studies in 
genetic animal models with targeted disruption of monoamine transporters suggest 
functional overlap between these transporters. Consequently, pharmacological and 
physiological characterizations to distinguish their role in psychiatric illnesses and drug 
abuse require proper understanding of the mechanisms regulating monoamine transporter 
function. 
A range of physiologic, pharmacologic, and activity-dependent mechanisms can 
regulate monoamine transporters acutely. Changes in the transporter activity or 
expression will have a significant impact on the duration and concentration of 
monoamines present in and outside the synaptic cleft. These changes, resulting in the 
regulation of transporter function, in tum would influence pre- and postsynaptic 
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responses to released monoamines. Several studies suggest the function at the level of 
gene transcription and translation (long-term or chronic regulation requiring hours or 
days) or posttranslational protein modifications (short-term or acute regulation requiring 
seconds to minutes) (Blakely, Ramamoorthy et al. 1997; Ramamoorthy 2002; Jayanthi 
and Ramamoorthy 2005). 
1.2.1 Chronic Regulation of Amine Transporters 
Structural analysis of transporter gene promoter regIons reveals a number of 
canonical transcription-binding sites that may be important in controlling the responses of 
the transporter gene to regulatory factors (Lesch, Balling et al. 1994; Kawarai, Kawakami 
et al. 1997; Fritz, Jayanthi et al. 1998; Flattem and Blakely 2000; Murphy, Lerner et al. 
2004; Kelada, Costa-Mallen et al. 2005; Marziniak, Mossner et al. 2005). Relevant 
investigations performed on JAR cells have shown that activation of cAMP-dependent 
(mimicked by cholera toxin, forskolin, dibutyrl cAMP) and -independent pathways 
(mimicked by staurosporine and interleukin-1~) increases 5-HT uptake. Increases in 5-
HT uptake require prolonged stimulation as well as messenger RNA and protein 
synthesis (Ramamoorthy, Ramamoorthy et al. 1995b; Ramamoorthy, Ramamoorthy et al. 
1995c). Similarly, angiotensin II increases NET activity at the level of regulating NET 
gene transcription (Lu, Yu et al. 1996). 
1.2.2 Acute Regulation of Amine Transporters 
Amino acid sequence analysis ofSERT, OAT, and NET proteins reveal numerous 
consensus sites for protein kinases as well as putative interactive motifs in cytoplasmic 
domains suggesting that second messengers are able to play a role in post-translational 
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regulation of monoamine transporters. Before the cloning of monoamine transporters, 
evidence suggested a pivotal role for second messenger-linked pathways in the acute 
modulation of neurotransmitter uptake (Ramamoorthy 2002). Potential pathways linked 
to second messenger-linked pathways might regulate transporter function acutely. 
Multiple reports have demonstrated a capacity of native and heterologously expressed 
amine transporters to be regulated rapidly following acute elevation/depletion of 
intracellular Ca2+, treatment with calmodulin inhibitors, or via activation of PKC, 
NOS/cGMP, and MAPK pathways. Since the second messenger-linked pathways noted 
above can be linked to presynaptic receptors, these pathways may provide 
positive/negative feedback mechanisms in control of amine clearance in vivo (Blakely, 
Ramamoorthy et al. 1998; Ramamoorthy 2002; Melikian 2004; Zahniser and Sorkin 
2004; Blakely, Defelice et al. 2005; Jayanthi and Ramamoorthy 2005). 
Mechanisms o/Short-Term Monoamine Transporter Regulation 
Regulation of transport function can occur directly by phosphorylation of 
transporter proteins. Phosphorylation of transporter proteins might in tum change 
intrinsic transport activity, turnover rate, plasma membrane insertion by modulating 
exocytic fusion and/or sequestration from the plasma membrane by modulating endocytic 
machinery. Alternatively, transporters can be regulated through their association with 
other interacting proteins by phosphorylation-dependent or -independent pathways. 
Substrate or antagonist binding may also modulate transport activity via its influence on 
transporter phosphorylation, trafficking, and interaction with transporter-interacting 
proteins. Post-translational modifications such as glycosylation, phosphorylation, and 
ubiquitination regulate monoamine transporter function and expression levels (Vaughn, 
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Huff et al. 1997; Ramamo orthy , Giovanetti et al. 1998; Jayanthi, Samuvel et al. 2004; 
Jiang, Jiang et al. 2004; Li, Chen et al. 2004; Miranda, Wu et al. 2005). In addition, 
variations in monoamine transporter gene sequences known as polymorphisms may also 
alter transporter expression levels, activity and/or regulation. Recent studies demonstrate 
that the activity and expression of monoamine transporters are regulated by 
phosphorylation and dephosphorylation of transporter proteins. Thus, monoamine 
transporters are dynamically regulated by intracellular and extracellular regulation of the 
phosphorylation state, which in tum significantly impacts the duration and concentration 
of monoamines present in and outside the synaptic cleft. 
1.2.3 Regulation of Monoamine Transporter Trafficking 
Among various stimuli that acutely regulate monoamine transporters, the majority 
regulates transport function by altering transporter surface expression. Activation of 
PKC pathways by phorbol esters reduces 5-HT, NE, and DA transport capacity and the 
number of binding sites on the cell surface [for reviews, see (Gulley and Zanheiser 2003; 
Mortensen and Amara 2003)]. Presynaptic receptor activation such as NKI activation 
leads to activation of PKC, and subsequently downregulation of DAT and NET. DA 
itself regulates DAT, directly by downregulating surface expression, or indirectly by 
upregulating the DA T via D2 dopamine autoreceptors [for review, see (Wu, Reith et al. 
2002; Gulley and Zanheiser 2003)]. Using PKC isoform-specific inhibitors as well as co-
expression studies reveals the involvement of classical PKC~II in DAT downregulation. 
DA T function is also regulated by arachidonic acid, ethanol, tyrosine kinase 
activator/inhibitors, and nitric oxide (Lonart and Johnson 1994; Zhang and Reith 1996; 
Mayfield and Zanheiser 2001). Analogous PKC-mediated transporter redistribution has 
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been detected for NET and SERT (Kitayana, Dohi et al. 1994; Zhang, Coffey et al. 1997; 
Apparsundaram, Galli et al. 1998a; Apparsundaram, Schroeter et al. 1998b; Jayanthi, 
Samuvel et al. 2004). In transformed cell line SK-N-SH cells, where NET is expressed 
endogenously, activation of muscarinic acetylcholine receptors also results in NET down-
regulation. Moreover, inhibition of PKC by antagonists abolishes PKC-mediated effects 
but produces only partial blockade of methacholine-mediated effect. PKC activation and 
pathways dependent on mobilization of Ca2+ stores are involved in muscarinic receptor-
mediated NET regulation (Apparsundaram, Galli et al. 1998a). Thus, studies show the 
existence of PKC-independent regulatory pathways supporting NET surface expression 
and/or intrinsic transporter catalytic activity. 
Downregulation of transporters by PKC may be present but could occur across a 
different time frame. Indeed, recent studies using natively expressed SERT in platelets 
show diminished catalytic activity before an enhancement of SERT endocytic rate that 
ultimately reduces cell-surface SERT expression. Thus, these findings suggest that PKC 
activation regulates SERT in bi-phasic manner, where the initial phase of inhibition 
occurs independent of trafficking and the later phase characterized by an enhanced 
endocytosis. 
Hormones and trophic factors acting through tyrosine kinase-linked receptors 
have also been implicated in monoamine transport regulation. Insulin regulates NE 
transport (Boyd, Clarke et al. 1985; Boyd, Clarke et al. 1986; Figelwicz, Szot et al. 1993; 
Figelwicz, Szot et al. 1994; Figelwicz, Patterson et al. 1999). Recent work also shows 
regulation of DAT functional by insulin, presumably through PI3-kinase (which is 
activated by the insulin receptor) (Carvelli, Moron et al. 2002) and downstream Akt 
I 
17 
(Garcia, Wei et al. 2005); this presumably plays a role in effects of food restriction on 
psycho stimulant reinforcement. In the case of NET, MAPKs are involved, differentially 
regulating NET function by trafficking-dependent and -independent mechanisms 
(Apparsundaram, Sung et al. 2001). 
Not only NET (Apparsundaram, Sung et al. 2001) but also DAT (Carvelli, Moron 
et al. 2002) and SERT (Zhu, Hewlett et aL 2004; Samuvel, Jayanthi et al. 2005) are 
regulated by MAPKs. While studies on DAT (Moron, Zakharova et aL 2003) and SERT 
(Samuvel, Jayanthi et al. 2005) implicate MAPK effects on transporter trafficking, other 
studies on NET and SERT indicate modulation of transporter catalytic activity. p38 
MAPK-mediated SERT redistribution involves enhanced plasma membrane insertion of 
the transporter (Samuvel, Jayanthi et al. 2005). Numerous studies have indicated 
alterations in 5-HT levels, SERT binding sites, and serotonergic neuronal firing in 
response to numerous stressors (Chaouloff, Berton et al. 1999) such as anisomycin-D, 
ultraviolet light, and free radicals. Thus, the regulation of SER'r by p38 MAPK, a stress-
induced kinase, may provide a novel presynaptic mechanism in maintaining appropriate 
synaptic 5-HT levels during stressful conditions. Several studies indicate that SERT is 
upregulated by a cGMP/PKG-mediated pathway through altered surface expression 
(Miller and Hoffman 1994; Kilic, Murphy et al. 2003; Zhu, Hewlett et al. 2004). 
Interestingly, MAPK effects on SERT intrinsic activity are also sensitive to PKG activity 
(Zhu, Hewlett et al. 2004). Thus, monoamine transporters are subjected to multiple, 
interacting modes of kinase-dependent modulation via trafficking-dependent and 
trafficking-independent mechanisms. 
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1.2.4 Altered Transporter Phosphorylation 
Recent studies on monoamine transporters reveal that changes in activity and 
expression are regulated by transporter phosphorylation and dephosphorylation. Thus, 
the transporters are dynamically regulated by intracellular and extracellular regulation of 
phosphorylation states, which in tum should have a significant impact on the duration and 
concentration ofmonoamines, present extraneuronally. DAT, SERT, and NET proteins 
are phosphorylated in response to PKC activation (Vaughn, Huff et al. 1997; 
Ramamoorthy, Giovanetti et al. 1998; Jayanthi, Samuvel et al. 2004). SERTs are 
phosphorylated following PKC and PKA activation and protein phosphatase 2A (PP2A) 
inhibition. DA T proteins are also phosphorylated in transfected cells and synaptosomal 
preparations following treatment with PKC activators and PP2A inhibitors (Huff, Vaughn 
et al. 1997; Vaughn, Huff et al. 1997). The PKC-dependent phosphorylation effect 
shows a close temporal correlation with reduction in transport capacity (Ramamoorthy, 
Giovanetti et al. 1998; Ramamoorthy and Blakely 1999). SERT substrates and 
antagonists influence PKC-dependent SERT phosphorylation and surface redistribution 
(Ramamoorthy and Blakely 1999). Recent studies indicate that while PKC activation 
increases SERT basal phosphorylation, p38 MAPK inhibition decreases SERT basal 
phosphorylation, indicating a role for p38 MAPK-induced phosphorylation in constitutive 
SERT expression (Samuvel, Jayanthi et al. 2005). More recently, investigations from our 
laboratory identified a previously unidentified biphasic regulation of endogenous SER Ts 
expressed in platelets (J ayanthi, Samuvel et al. 2005). The findings from this study 
suggest that PKC activation regulates SERT in a biphasic manner, where the initial phase 
of inhibition occurs independent of trafficking and the later phase is characterized by and 
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enhance endocytosis. The biphasic inhibition of SERT is accompanied by a sequential 
phosphorylation of plasma membrane-resident SERT initially on serine residue(s) and 
then on threonine residues( s), suggesting that the initial phosphorylation on serine 
residues might be responsible for changes in the intrinsic properties andlor silencing of 
SERT and that the phosphorylation on threonine residues later on might trigger 
internalization of phosphorylated SERT. 
DAT is phosphorylated on N-terminal serine residues (Foster, Paranusorn et al. 
2002). The PKC-mediated internalization of monoamine transporters occurs in parallel 
to enhance phosphorylation of the transporter. Although the transporters undergo 
phosphorylation in response to PKC activation or PP1/2A inhibition, it is not known 
whether phosphorylation of the transporter leads to its internalization. However, recent 
studies using phospho-site mutants of transporters provided positive as well as negative 
correlations between phosphorylation and transporter functional regulation (Bonisch, 
Hammermann et al. 1998; Whitworth and Quick 2001b; Granas, Ferrer et al. 2003; Lin, 
Zhang et al. 2003). Studies demonstrate that tyrosine kinase activity is also critical in 
maintaining NET (Apparsundaram, Sung et al. 2001), DAT (Doolen and Zanheiser 
2001), and GAT (Law, Stafford et al. 2000; Whitworth and Quick 2001a) cell-surface 
levels. Phosphorylation of YI 07 and Y317 on y-aminobutyric acid transporter (GATI) is 
required for tyrosine kinase-mediated y-aminobutyric acid (GABA) transport regulation 
(Whitworth and Quick 200Ia). Interestingly, the reciprocal relationship between PKC-
and tyrosine kinase-mediated GA TI phosphorylation suggests that a balance between 
these two states of phosphorylation may dictate relative abundance of GA Tl on the cell 
surface (Quick, Hu et al. 2004). 
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While a part of the N-terminal domain appears to interact with syntaxin lA 
involved in PKC-mediated regulation (Sung, Apparsundarma et al. 2003), determinants 
within the C-terminus of human NET (hNET) dictate NET trafficking, stability, and 
activity (Bauman and Blakely 2002). Interestingly, nonclassical endocytic signals dictate 
constitutive and PKC-regulated internalization of DA T (Holton, Loder et al. 2005; 
Sorkina, Hoover et al. 2005). These signals are conserved in NET. However, it is not 
known whether there is a relationship between NET phosphorylation and PKC-induced 
transporter regulation. NET protein contains multiple consensus sites for several kinases 
including PKC that are distinct from those present in DAT or SERT, and therefore, NET 
may be regulated by mechanisms that are different than those ofDAT and SERT. Recent 
work by our lab (Jayanthi, Annamalai et al. 2006) demonstrates that a PKC-site mutant of 
hNET is resistant to PKC-mediated downregulation and phosphorylation. This study 
provides the first evidence that phosphorylation of a PKC motif on a monoamine 
transporter is linked to transporter internalization. In addition this PKC-site mutant of 
hNET exhibits altered transport properties such as increased affinity for NE and 
substrate-like ligand D-amphetamine and decreased affinity for inhibitory ligands such as 
cocaine, desipramine, and nisoxetine. Phospho-site mutations could contribute to altered 
NE transport process due to physical conformational changes occurring as the result of 
mutation or the altered phosphorylation state itself. Such changes can result in the 
second intracellular loop reported altered ligand-binding properties attributed to structural 
changes in the physical conformation of DAT protein (Goldberg, Beuming et al. 2003; 
Uhl and Lin 2003; Fornes, Nunez et al. 2004; Loland, Granas et al. 2004). More recently 
we have discovered a putative PKG phosphorylation site in SERT within intracellular 
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loop-2 (IL2) which has been found to be correlated with an increase in SERT uptake of 5-
HI upon cGMP activation by various agonists. Such investigations would prove useful 
in developing antidepressant drugs with higher efficacy and reduced potential side 
effects. 
1.2.5 Regulated Protein-Protein Interactions 
Monoamine transporters can act as a single unit, self-associate, or bind to other 
proteins. As described earlier, agents that maintain the phosphorylated state modulate 
amine transporter activity. For example, inhibition of PPI/PP2A by okadaic acid (OA) 
downregulates SERT, DAT, and NET activity. Phosphorylation state and regulation of 
amine transporters is a balance between the actions and localization of protein kinases 
and protein phosphatases. The pronounced effect of PPI/PP2A inhibition on amine 
uptake and amine transporter phosphorylation suggests the possible physical association 
off PPI/PP2A as a regulatory complex with amine transporter proteins. Indeed, physical 
complexes containing biogenic amine transporter and PP2Ac protein were recently 
demonstrated (Bauman, Apparsundaram et al. 2000). The SERTIPP2A complex is 
disrupted by PP 1 IPP2A inhibitors as well as PKC activators and can be stabilized by the 
SERT substrate 5-HT, suggesting that modulation of SERT/phosphatase association is 
involved in regulated transporter phosphorylation and trafficking. Similar transporter and 
PP2Ac associations were found for DA T and NET proteins. Analogous to findings in 
SERT studies, PP2Ac association with NET in vas deferens was also decreased by PKC 
activation and PPI/PP2A inhibition. 
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While direct phosphorylation and/or dephosphorylation of transporters by cellular 
protein kinases and phosphatases is involved in the dynamic regulation and expression of 
transporters, other integral membrane proteins also appear to play an important role in 
trafficking and catalytic function of transporters. The first evidence for the physical 
association of GAT1 GABA transporter with (t)-SNARE protein syntaxin-1A as a 
complex comes from studies by Quick and his coworkers (Deken, Beckman et al. 2000; 
Horton and Quick 2001). DAT, SERT, and NET are also physically associated with 
syntaxin-IA (Haase, Killian et al. 2001; Sung, Apparsundanna et al. 2003; Lee, Kim et 
al. 2004; Samuvel, Jayanthi et al. 2005). Using noradrenergic tissues such as vas 
deferens and transfected cell lines, it was reported that syntaxin-1A is found in NET 
immunoprecipitates (Sung, Apparsundanna et al. 2003). Activation of PKC or 
phosphatase inhibition decreases sytaxin-IA level with NET. Altering intracellular Ca2+ 
also regulates syntaxin-IAINET interaction. P38 MAPK inhibition and PKC, activation 
decreases SERT and syntaxin-l A interactions in rat brain synaptosomes (Samuvel, 
Jayanthi et al. 2005). Together these findings suggest an important role for syntaxin-IA 
in neurotransmission by regulating both transmitter release and reuptake. 
DAT interacts with several regulatory proteins, including a-synuclein, syntaxin-
lA, and PICK1. Monoamine transporters also exist in oligomeric forms, but their 
functional significance is not known (Schmid, Scholze et al. 2001; Norgaard-Nielsen, 
Norregaard et al. 2002; Torres, Carneiro et al. 2003). Certain intracellular proteins such 
as PICK1 (protein-1 that interacts with C-kinase) and a-synuclein also interact with DAT 
to stabilize its cell-surface expression (Torres, Yao et al. 2001; Sidhu, Wersinger et al. 
2004). Signals following presynaptic receptor stimulation may influence transporter 
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function and expression by regulating the stability of transporter heteromeric complexes. 
Studies show interaction of PDZ domain-containing protein PICKI with C-terminal 
cytoplasmic domains ofDAT and NET (Torres, Yao et al. 2001). Co-expression ofDAT 
and PICKI enhances DAT activity and PICKI co-immunoprecipitation with DAr. 
Confocal microscopy analysis reveals colocalization of both DAr and PICKI in 
heterologous systems and in dissociated dopaminergic neurons. Since PICKl is a PKC-
binding protein, it is possible that PICKl acts like an adaptor to bring PKC near OAT 
proteins, which in tum could regulate PKC-evoked OAT phosphorylation, trafficking, 
and function. Such DAT and PKCPII interactions have been recently demonstrated 
(Johnson, Guptaroy et al. 2005). a-synuclein is enriched in dopaminergic nerve terminals 
and has been implicated in Parkinson's and other neurodegenerative disorders 
(Polymeropoulos, Lavedan et al. 1997). a-synuclein binds directly to the C-terminal 
region of OAT and facilitates plasma membrane clustering and increase in OAT activity 
(Lee, Liu et al. 2001; Wersinger, Vernier et al. 2004). This study suggests that the a-
synucleinlDAT complex regulates normal dopaminergic neurotransmission and altered 
interactions may result In abnormal DA T function caUSIng dopaminergic 
neurodegeneration seen in Parkinson's disease. DAT also interacts with LIM domain-
containing adapter protein, Hic-5 (Carneiro, Ingram et al. 2002). Hic-5 is known to 
interact with signaling molecules such as nonreceptor protein tyrosine kinases focal 
adhesion kinase (F AK) and FYN. This raises the possibility that Hic-5 may be involved 
in tyrosine kinase-mediated OAT regulation. Together, these studies indicate that 
protein-protein interactions play an important role in influencing transporter 
phosphorylation, trafficking, and intrinsic activity. 
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1.2.6 Substrates and Antagonists Effects on Monoamine Transporters 
Amine transporter substrates and antagonists are known to regulate transporter 
function and expression (Bernstein and Quick 1999; Munir, Correale et al. 2000; Quick 
2002; Samuvel, Jayanthi et al. 2005). Since transporters are subjected to phosphorylation 
by multiple kinase-dependent modulations, it is possible that substrates may also 
influence transporter surface expression by regulating kinase-mediated transporter 
phosphorylation. For example, SERT substrates such as 5-HT, amphetamines, and 
fenfl uramine and antagonists such as antidepressants and cocaine control PK C-dependent 
SERT phosphorylation and surface redistribution (Ramamoorthy and Blakely 1999). 
Transporting of SERT substrates, 5-HT, amphetamine, and fenfluramine protect SERT 
from PKC-linked phosphorylation and sequestration. The effect of 5-HT on SERT 
dependent but not 5 -HT receptor-dependent, and the nontransported ligands such as 
cocaine and antidepressants block the effect of 5-HT. Interestingly, amphetamines 
substitute for substrates in suppressing PKC-mediated SER l' phosphorylation. Such 
action could override homeostatic transporter sequestration processes and provide for 
psychostimulant sensitization by increasing the number of psychostimulant targets 
available to a subsequent stimulus. On the other hand, nonpermeant SERT ligands 
including SSRIs and cocaine that prevent 5-HT permeation block the effect of 5-HT 
uptake but also by shifting the cellular-distribution of SERT. D-Amphetamine, which is 
also a substrate for SERT, increases SERT basal phosphorylation that is sensitive to p38 
MAPK inhibition suggesting that p38 MAPK may govern substrate-mediated effects on 
SERT basal phosphorylation (Samuvel, Jayanthi et al. 2005). 
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NET proteins are downregulated following chronic treatment (3 days) with the 
NET substrate NE, amphetamine, and antagonist desipramine, perhaps through changes 
in protein expression and/or NET turnover (Zhu and Ordway 1997; Zhu, Shamburger et 
al. 2000; Ordway, Jia et al. 2005). 
OAT antagonists and substrates differentially modulate basal and PKC-mediated 
OAT phosphorylation in rat brain synaptosomes and OAT-expressing cell lines. Acute 
exposure to transporter substrates reduces DAT membrane expression, while brief 
treatment with transporter blockers increases DAT cell-surface expression. In addition, 
the regulation of DA T trafficking has been shown to tightly correlate with the functional 
regulation of DA transport capacity. Amphetamines trigger DAT internalization 
(Saunders, Ferrer et al. 2000), and while acute cocaine exposure increases DAT surface 
levels (Daws, Callaghan et al. 2002; Little, Elmer et al. 2002), amphetamine-induced 
DAT internalization is blocked by cocaine (Saunders, Ferrer et al. 2000). This inverse 
relationship between antagonist binding and substrate translocation suggest that various 
transporter conformational states may promote or preclude their engagement with cellular 
endocytic machinery, dictating transporter surface levels. 
Substrate translocation or ligand occupancy may influence the equilibrium of 
protein conformation required for transporter phosphorylation or transporter association 
with other regulators. Thus, a feedback loop may exist, providing a mechanism by which 
changes in extracellular neurotransmitter concentrations could rapidly modulate 
neurotransmitter transport capacity. This way, the control of transporter cell-surface 
expression by its substrates or ligands would provide a novel homeostatic mechanism in 
the neuron to fine-tune transport capacity to match demands imposed by fluctuating 
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levels of the neurotransmitter. Signaling pathways linked to presynatpic auto- and 
heteroreceptors could provide a positive/negative feedback control and provide a 
mechanism by which changes in extraneuronal neurotransmitters could rapidly modulate 
transport capacity of the transporter. Altered or inappropriate regulatory mechanisms 
may contribute to transporter dysregulation described in psychiatric and other disorders. 
Any disturbance in the homeostatic regulatory mechanism, for example by 
antidepressants or psycho stimulants, would be predicted to alter the normative 
physiological regulation of 5-HT levels and potentially produce pathological or 
therapeutic effects. Determining the mechanism by which transporter substrates and 
blocker affect transporter cell-surface expression is certain to be important for the 
development of new therapies for the treatment of psychiatric illnesses, drug abuse, as 
well as other disease states such as ADHD and Parkinson's disease. 
Monoamine Transporter in Addiction 
Monoamine transporters are also of particular interest in the field of addiction 
because they constitute high-affinity molecular targets mediating the cellular and 
behavioral effects of psycho stimulants such as amphetamine and cocaine (Reith, Meisler 
et al. 1986; Seiden, Sabol et al. 1993). Repeated use of certain transport inhibitors, such 
as cocaine, can eventually lead to compulsive drug-seeking behavior. Given the 
importance of monoamine transmission in various aspects of addiction, and the profound 
influence that monoamine transport has on the extracellular levels of monoamines, as 
well as intracellular monoamine homeostasis, long-term changes in transporter level, 
kinetics, or regulation would be expected to greatly influence spontaneous and drug-
induced behaviors. This possibility is clearly evidenced by the large effects on drug-
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induced behaviors, as well as on neurotransmitter synthesis, storage, and release by 
removing monoamine transporter genes in mutant mice (Giros, Jaber et al. 1996; Bengel, 
Murphy et al. 1998; Rocha, Faumagalli et al. 1998; Sora, Wichems et al. 1998). 
Receptors that are known to influence amine transporter functions, such as 5-HT1B 
(SERT), and D2, opioid, or mGluR5 (OAT) have been implicated in cocaine sensitization 
(Nestler and Aghajanian 1997; Pierce and Kalivas 1997; Thompson, Zapata et al. 2000; 
Page, Peeters et al. 2001). Such changes in receptor-linked signaling cascades could 
influence phosphorylation of transporters or associated proteins, and thereby transporter 
activity. Since the second messenger-linked pathway can be linked to presynatpic 
receptors, these pathways may provide positive/negative feedback mechanisms in control 
ofDA, 5-HT, and NE in vivo 
1.2.7 Dysregulation of Amine Transporters in Human Disease 
Biogenic amines 5-HT, DA, and NE control many behavioral and physiological 
functions in the eNS and PNS. Altered amines as well as amine transporters have been 
implicated in several psychiatric, neurodegenerative, and addictive disorders. Several 
other diseases and neuropsychiatric disorders are also likely to have genetic contributions 
from SERT, NET, and OAT. These include developmental disorders such as ADHD, 
autism, sudden infant death syndrome (SIDS), and Tourette's syndrome as well as 
equally complex disorders such as polysubstrate abuse, irritable bowel syndrome (IBS), 
primary pulmonary hypertension (PPH), and myocardial infarction. 
Two polymorphic regions, the long (I) and short (s) have been identified in the 
SERT promoter. The long (I) variant is associated with increased 5-HT uptake, and the 
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short (s) with low 5-HT uptake. The "s" variant plays a functional dominance over the 
long allele. SERT-linked promoter regions have been implicated in anxiety, mood 
disorders, alcohol abuse, and other neuropsychiatric disorders. The degree to which 
SERT-linked promoter variants influence SERT expression in vivo is controversial, with 
both supportive and contradictory evidence (Flattem and Blakely 2000; McCauley, Olsen 
et al. 2004). A recent search for sequence variants in the SLC6A4 gene, encoding SERT, 
uncovered 15 variants in genomic DNA from a population of 450 individuals in the DNA 
Polymorphism Discovery Resource (Ozaki, Goldman et al. 2003). Of these, six were 
synonymous and the remaining nine resulted in an amino acid changes (Thr3Ala, 
Gly56Ala, Leu255Met, Ser293Phe, Pr0339Leu, Leu362Met, Ile425Val, Lys605Asn, and 
Pro621Ser). Dennis Murphy of NIMH reported that two unrelated probands and their 
family members with OCD contained the Ile425Val coding variant carried on the 5-
HTTLPRll/l background (Ozaki, Goldman et al. 2003). In functional studies, this 
variant has been found to exhibit elevated 5-HT uptake activity without any changes in 
SERT surface expression and was insensitive to stimulation by nitric oxide donors in 
transfected cells. Recently, Blakely's group identified several other human variants that 
are linked to autistic disorder (Prasad, Zhu et al. 2005; Sutcliffe, Delahanty et al. 2005). 
Human SERT variants T4A and G56A, failed to show 5-HT uptake stimulation when 
tested with 8-Br-cGMP and anisomycin, typical of wild-type hSERT. Importantly, in a 
physiologically relevant human cell model, such as Epstein-Barr Virus (EBV) .. 
transformed lymphocyte natively expressing the most common of these variants 
(Gly56Ala), a loss of 5-HT uptake stimulation by PKG and p38 MAPK activators was 
observed. Furthermore, HeLa cells transfected with the Gly56Ala variant exhibited 
29 
elevated basal phosphorylated and, unlike wild-type SERI', could not be further 
phosphorylation after 8-Br-cGMP treatment (Prasad, Zhu et al. 2005). On the basis of 
these findings, it is hypothesized that obsessive compulsive disorder (OCD) and autistic 
subjects carrying mutant SER T show elevated levels of SER T expression as if they were 
being stimulated constitutively through a cGMP-linked pathway. 
The hNET gene is a single-copy gene (SLC6A2) located on chromosome 16 and 
(Hahn and Blakely 2002b) containing 16 exons. A number of hNET promoter, intron, 
and coding region polymorphisms have been identified through both discovery-oriented 
studies of hNET in various clinical populations or during the course of genome 
sequencing efforts (Hahn and Blakely 2002b). To date, approximately 20 non-
synonymous single nucleotide polymorphisms (SNPs), which result in amine acid 
substitutions, have been reported in hNET. Many of these variants were derived from 
psychiatric and cardiovascular phenotypes, yet only a limited number has been examined 
for alterations in expression or function (Halushka, Fan et al. 1999; Runkel, Bruss et al. 
2000; Stober, Meyer et al. 2000; Iwasa, Kurabayashi et al. 2001). In a familial form of 
orthostatic intolerance, Blakely's laboratory identified a nonsynonymous hNET SNP that 
produces the protein variant, A457P, a loss of function, dominant-negative transporter 
that contributes to increased heart rate, high plasma NE levels, and reduced systemic NE 
clearance. This study demonstrates the impact of the hNET coding variant on NE 
clearance contributing to increased heart rate, high plasma NE levels, and reduced 
systemic NE clearance (Shannon, Flattem et al. 2000). This study demonstrates the 
impact of the hNET coding variant on NE clearance contributing to a human disease 
condition. Another recent study from Blakely's laboratory revealed striking effects of 
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these naturally occurring SNPs on transporter protein expression, substrate transport, 
antagonist interaction, and regulation by kinase-mediated signaling pathways. Of 
particular interest are hNET F528C and hNET R121Q variants identified in some 
cardiovascular phenotypes that showed altered regulation by the PKC-mediated pathway. 
While F528C was insensitive, R121Q was more sensitive to PKC-dependent regulation 
suggesting that similar mechanisms may underlie differences observed in both basal and 
regulated transport (Hahn, Mazei-Robison et al. 2005). These findings signify the search 
for underlying mechanisms of transporter regulation by signaling pathways in normal 
physiology and pathophysiology. 
Altered DA T function or density has been implicated in various types of 
psychopathology, including depression, suicide, anxiety, aggression, and schizophrenia 
(Eichelman 1990; Carlsson, Waters et al. 2001; Comings 2001; Meyer, Goulding et al. 
2002). Associations between DAT gene polymorphisms and human disorders with 
possible links to the DA system, including ADHD and consequences of cocaine and 
alcohol abuse, have been reported (Miller, De La Garza et al. 2001). Although the 
coding region of the human DAT gene contains very limited genetic variation, variants of 
the DAT gene may exist, and possibly arise from RNA editing or via other mechanisms 
(Miller, De La Garza et al. 2001). A repeat sequence in the 39-untranslated region (39-
URT) of the human DAT is associated with ADHD (Cook, Stein et al. 1995). A 
thorough examination of potential coding sequence variants in more than 150 unrelated 
individuals free of neuropsychiatric disease, or with Tourette's syndrome, a diagnosis of 
ethanol dependence, or ADHD (Vandenbergh, Thompson et al. 2000). The study did 
reveal a low frequency of two naturally occurring human DAT variants, i.e. V55A and 
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V382A (Vandenbergh, Thompson et al. 2000). In a subsequent report on COS cells 
expressing these variants, V55A was shown to display a lower Km for DA uptake 
compared with wild type, and V382 a lower Vmax (a dominant effect on expression 
observed also in the present of wild type) as well as lower affinity of DA for DAT as 
measured by inhibition of cocaine analog binding (Lin and UhI 2003). In a separate 
study of 91 healthy controls or subjects with bipolar disease, Grunhage and coworkers 
(2000) detected two rare missense substitutions and three silent mutations in the whole 
coding region of DAT. Altered transport properties associated with some of the coding 
variants of DA T suggest that individuals with these DAT variants experience functional 
changes in the DA system (Lin and UhI2003). 
-Above section taken/rom textbook review; Jayanthi et aI, 2007 
1.3 Oligomerization of monoamine transporters 
1.3.1. Monoamine Transporters are Oligomeric Structures 
It has been hypothesized that monoaminergic transporters exist in the plasma membrane 
of living cells in oligomeric form. Early studies showed that proteins that transverse 
membranes appear to have structures of higher order in which the units are arranged 
asymmetrically across the membrane and the axis of symmetry perpendicular to the 
membrane plane. This structure allows for the transporter to efficiently transport 
nutrients across the cell membrane in a favorable manner (Klingenberg 1981; Veenhoff, 
Heuberger et al. 2002). Other early evidence using radiation inactivation ofDAT showed 
that ligand binding sites appeared to be formed to accept ligands of larger molecular 
weight than the predicted amino acid sequence deduced size. For example, the apparent 
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target binding site size for "the cocaine binding site" as measured with the cocaine 
analogue 2 beta-[3H]carbomethoxy-3 beta-( 4-fluorophenyl)tropane was approximately 
140 kDa. Also binding sites of GBR-12935 and mazindol (a OAT inhibitor and a OAT 
substrate, respectively) after radiation inactivation were predicted to be larger than the 
aforementioned 70 kOa (Berger, Farrell et al. 1994). A later study by Ramamoorthy, et al 
using gel filtration chromatography showed that filtration fractions at higher molecular 
weights (::::::360 kOa) bound the SERT antagonist and SSRI, paroxetine, while this binding 
was not found at the expected 70 kOa, the molecular weight of monomer SERT. This 
suggests that SERT must exist as a higher order oligomer to bind drugs such as 
paroxetine (Ramamoorthy, Leibach et al. 1993). Further studies used heterologous 
expression of linear concatenates to help determine the quarternary structure of SERT. 
Up to four copies of SERT concatenates showed discernible uptake for the monomer, 
dimer, and tetramer but not the trimer. Interestingly, equivalent Km binding for cocaine 
with all four forms of SERT were shown including the non-functional trimer (Chang, 
Starnes et al. 1998). This data points to the possibility that while oligomerization is 
necessary for 5-HT uptake it is not necessary for inhibitor binding. Also, treatment of 
SERT expressed in HEK-293 cells with sulfhydryl oxidizing agents and 
homobifunctional cross-liner dimethylsuberimidate (DMS) created SERT complexes of 
130-180 kOa and 220-270 kDa, respectively, helping to create more evidence for the 
oligomerization of SER T (Hastrup, Karlin et al. 2001). These studies were followed by 
co-immunoprecipitation data using inactivation of SERT proteins with (2-
aminoethyl)methanethiosulfonate (MTSEA)-biotin which has been shown to modify 
external cysteine sulfhydryl groups. These studies revealed that SERT could be 
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expressed in higher oligomeric complexes such as tetramers (Kilic and Rudnick 2000). 
Another co-immunoprecipitation study observing the oligomerization of DA T used HA-
and 6-His-tagged wild-type and dominant-negatively formed DAT. Mutant DAT 
composed of the mutation of important sites within DAT, (i.e. Y335A and D79G, both of 
which are thought to be necessary for the function of the transporter) resulted in normal 
trafficking of SERT while decreasing the uptake of 5-HT by SERT. Truncated mutants 
at the C-terminal resulted in further impairment of the normal processing of 5-HT uptake 
with respect to oligomerization. Another step forward in understanding the molecular 
composition of monoamines is raised from the introduction of Fluorescence Resonance 
Energy Transfer (FRET). FRET imaging describes an energy transfer mechanism 
between two chromophores. FRET has been used previously to examine oligomerization 
of membrane proteins, including G protein-coupled receptors (Overton and Blumer 2000) 
and ion channels (Riven, Kalmanzon et al. 2003). FRET studies have revealed that 
monoamine transporters are most likely complexed in the endoplasmic reticulum (ER) 
during protein synthesis and that these homo- or hetero-oligomeric complexes, expressed 
on the plasma membrane of immortalized dopaminergic cell line IRB3AN27 could be 
internalized by phorbol esters and amphetamine (Sorkina, Doolen et al. 2003). In 
addition cysteine cross-linking studies have been performed to observe the quaternary 
structure of DA T revealing domains within the transporter that may contain specific for 
sites for oligomerization (Hastrup, Karlin et al. 2001; Norgaard-Nielsen, Norregaard et al. 
2002). Also, studies using dominant negative forms of transporters have been performed 
to help support the possibility of monoamine transporter oligomerization. Alternative 
splice forms of rNET were created by alternative reading frame transcription and resulted 
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in two splice forms of rat Net (rNET): rNETa and rNETb. rNETa resembles human NET 
(hNET) whereas rNETb (the alternative splice form) has an alternate C-terminus from 
rNETa and has no uptake ability. However when co-expressed with rNETa, rNETb 
decreased functional expression of the wild-type NET. Also when co-expressed with 
other members of the NSS-symporter family: rat gamma-aminobutyric acid transporter 
(rGATl), a rat serotonin transporter (rSERT), and a rat dopamine transporter (rDAT) 
creating chimera transporters, functional expression and neurotransmitter uptake was also 
decreased, however this was not found in glutamate/aspartate transporter also though to 
form oligomers (Kitayama, Ikeda et al. 1999). 
1.3.2 Possible Sites for Monoamine Transporter Oligomerization 
It has been hypothesized that there are certain structural motifs within the 
monoamine transporters that allow for possible transporter oligomerization. These motifs 
vary in their consistency and their presence within the NSS-family. 
The GxxxG Motif in TM6 
The G(V/I)xxG(V/I) xx(AlT) or GxxxG motif originally identified in glycophorin 
A, a protein found in red-blood cells (Lemmon, Treutlein et al. 1994), has been identified 
in TM6 of DA T and is mostly conserved in other amino acid sequence in other NSS-
family members such as OAT, NET, SERT, and GAT-I. The second glycine (0) of the 
GxxxG motif is conserved in all NSS-family members and is indispensible for 
oligomerization. It is possible that since this motif (a.a. 323-327) contains an 
extracellular portion that is possibly reactive to disulfide crosslinking, there is a possible 
opportunity of TM6-TM6 oligomerization of two DAT transporters. Mutation of the 
35 
G327 to valine (G327V) disrupts proper plasma membrane trafficking of OAT and 
therefore appears to be an important residue in normal SERT activity (Hastrup, Karlin et 
al. 200 1). It has been reported that thiol retention within the ER is the mechanism behind 
whether or not proteins are permitted to be exported from the ER. In other words, 
monitoring the redox state of cysteine residues of proteins being processed in the ER is 
one gatekeeping step to creating properly folded and glycosylated proteins. Therefore it 
can be extrapolated that mutation of various sites within monoamine transporters could 
be targeted by the thiol retention system and subsequently never allowed to leave the ER, 
and therefore never expressed on the plasma membrane. It is also possible that improper 
oligomerization may be a cause for the alarm of the thiol retention system (Reddy and 
Corley 1998). Therefore proper folding and oligomerization may be necessary for the 
export of OAT and other similar transporters, such as SERT and NET, from the ER. 
Transmembrane Domain 4 of DAT 
Another symmetrical interface exists in TM4 of OAT. Cysteine depletion was 
conducted by site-directed mutagenesis and only cysteines in TM4 (Cys243) and TM6 
(Cys306) were left unmutated. Cysteine cross-linking experiments were then performed 
and bands corresponding to dimer, trimers, and tetramers were expressed in SDS-P AGE 
gel electrophoresis, much like in wild-type transporters without cysteine depletion. This 
indicated that there are possible oligomerization sites between TM-4 and TM-6 in OAT. 
This would allow OAT to oligomerize in a "dimer of dimers" form. While theoretically 
possible, it is unfeasible to believe that OAT would exist in a larger quaternary structure 
than a tetramer, most likely because the size of the protein would be too large for export 
from the ER (Hastrup, Sen et al. 2003). It is also possible that because N- and C-termini 
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of DA T and other family transporters interact with other proteins, it is possible that this 
could limit the extended oligomerization array as well. 
The Leucine Heptad Repeat in TM2 is involved in the oligomerization of monoamine 
transporters 
The leucine heptad motif, or the "leucine zipper", appears in many different 
proteins and is thought to be a source of protein oligomerization. The leucine heptad 
repeat appears in these different proteins with the generic formula: 
LxxxxxxLxxxxxxLxxxxxxL 
Where "L" stands for Leucine and "x" stands for any of six random residues that are 
usually hydrophobic in nature (McCormack, Tanouya et al. 1991). This leucine heptad 
repeat was first characterized in soluble transcription factors (Garcia, Nakai et al. 1997). 
It was found later that four tandem leucine heptad repeats were responsible for the 
dimerization of phospholamban, a modulator of the Ca2+ pump in cardiomyoctes (Sahin-
roth, Lawrence et al. 1994; Loland, Norregaard et al. 2002). It was later proposed by 
Gurezka et aI, that leucine heptad repeats found in transmembrane region domains were 
responsible for the oligomerization of plasma membrane proteins, and mutation of these 
leucine sites to alanines disrupted oligomerization (Gurezka, Laage et al. 1999). More 
recently the leucine zipper motif has been found to regulate oligomerization AKAP-LbC, 
a member of the A-kinase anchoring protein (AKAPs) family, which functions as a 
cAMP-dependent protein kinase (PKA)-targeting protein as well as a guanine nucleotide 
exchange factor (GEF) for RhoA (Baisamy, lurisch et al. 2005). Therefore, the nature of 
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the leucine amIno residue side chain may be important for causIng or stabilizing 
oligomerization of transmembrane regions. 
Leucine placement in the leucine heptad repeat allows the possibility of 
interaction with other transmembrane domains in the protein (McCormack, Tanouya et 
al. 1991). The six hydrophobic amino acid residues that are placed in between the 
individualleucines allow for the formation of a hydrophobic pocket. Leucine side chains 
(which are relatively long and hydrophobic) can then insert themselves into the 
hydrophobic pocket of an adjacent identical transmembrane region creating a "zipper .. 
like" motif (Macara and Cantley 1981). Alanine mutation of leucines would eliminate 
the side chain interaction with adjacent transmembrane regions therefore possibly 
disrupting the "zippering" of transmembrane domain regions. Since it appears that 
oligomerization is necessary for monoamine transporters to be expressed on the plasma 
membrane surface, the intact leucine zipper may provide an important role in achieving 
this expression. 
It appears that both DAT (Zhou, Merianos et al. 2001) and GAT-l (Burant and 
Bell 1992; Fafoumoux, Noel et al. 1994) have been found to have leucine zipper repeats 
within the transmembrane region 2 (TM2) and upon disruption of the zipper by alanine 
mutation, uptake of DA and GABA is completely obliterated and extinguishes 
oligomerization of these proteins. While SERT has not been studied there does appear to 
be an imperfect leucine zipper located within TM2 as well. However several problems 
arise to this being a strong possibility for an oligomerization site. 1) It is buried within a 
transmembrane domain region and it has been thought that there is limited association of 
polyleucine segments in the lipid bi-Iayer (Zhou, Cocco et al. 2000). 2) It has been 
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reported that leucine heptad repeats in ion channels, such as L-type calcium channels, are 
more involved in gating than in oligomerization (McCormack, Tanouya et al. 1991). 
Therefore, the role of the leucine heptad repeat in NSS-family transporters while 
conserved needs more study. 
The COOH- and NH2- terminus ofSERT may contain possible oligomerization sites 
FRET microscopy has been used to study the C- and N- termini of monoamine 
transporters. The N- and C- terminal of SERT when tagged with two different 
fluorophores of different wavelengths (CFP and YFP) can create a FRET signal, a signal 
that is only possible if the two fluorophores are in the correct orientation and distance, 
both of which are not left to chance (Just, Sitte et al. 2003). It has been shown through 
FRET donor bleaching that oligomerization sites possibly exist in both TMI/TM2 and 
TMII/TM12, the N- and C- termini respectively (Just, Sitte et al. 2003). Also another 
GxxxG motif is found in TM12 of SERT, but is not found in other NSS-family members. 
However because of the interaction of other proteins with these termini on the 
transporters, the ability of these sites to undergo oligomerization is not understood and 
warrant further investigation. 
1.4 Hypothesis and Overview 
The major hypothesis put forward in the dissertation is that oligomerization of 
SERT can be regulated through phosphorylation by c~llular protein kinases and 
phosphatases. As already discussed in this chapter both oligomerization and 
phosphorylation are important processes underlying monoamine transporter function, and 
trafficking-dependent and -independent regulation. . The ability to understand this 
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information and understand their interaction may lead to potential therapeutic agents that 
can help treat the aforementioned disorders. 
In Chapter 3.1 we hypothesized that activation of protein kinases such as PKG, 
p38 MAPK, and PKC regulate SERT oligomerization. We tested this hypothesis using 
various molecular techniques aimed at understanding whether these kinases had effects 
on the status of SERT oligomerization. Results revealed that kinases including PKG and 
p38 MAPK, that have been found to stimulate SERT-mediated 5-HT uptake, decrease 
SERT oligomerization, and PKC, which has been shown to down-regulate SERT 
function in concert with trafficking -dependent and -independent plasma membrane 
expression of SER T, caused an increase in SER T oligomerization. 
In Chapter 3.2, we then explored whether SERT phosphorylation is required for 
regulation of SERT oligomerization. To study this we used site-directed mutagenesis to 
direct point mutations at Thr276, the site we discovered was the only site in SERT for 
PKG-dependent phosphorylation. Studies showed that mutation of Thr276 to aspartic 
acid (T276D) created an increase in SERT uptake compared to controls and a decrease in 
SERT oligomerization while this was not observed for the alanine mutation of Thr276 
(T276A). 
Lastly, Chapter 3.3 we studied whether human mutant polymorphisms within 
SERT, that have been found in patients with various disorders, influences SERT 
oligomerization. Also, in this section we studied the effect of the drug of abuse, cocaine, 
on SER T oligomerization and the importance of SER T oligomerization for protein 
synthesis and ER exportation. 
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Chapter II. Materials and Methods 
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Materials 
8-Br-cGMP was from Sigma (St. Louis, MO). eH]5-HT (5-hydroxy-[3H]tryptamine 
trifluoroacetate), ECL reagent, and ECL enhanced film were obtained from Amersham 
Biosciences (Piscatway, NJ). All cell culture media and other reagents were purchased 
from Invitrogen (Carlsbad, CA) HRP-conjugated secondary antibodies were obtained 
from Jackson ImmunoResearch Laboratories (West Grove, PA) Anti-calnexin was from 
Stressgen, (Victoria, Canada). The QuickChange site-directed mutagenesis kit was from 
Stratagene (La Jolla, CA). Rp-8-pcPT-cGMPs and KT5720 were from BIOMOL 
(Plymouth Meeting, PA). KT5823 was from Fisher (Waltham, MA). Ni-NTA Superflow 
Nickel-Column Beads were from Qiagen (Valencia, CA). ~-PMA was from Alexis 
(London, UK), PD 169316 was from Calbiochem (San Diego, CA). All other reagents 
were of the highest grade possible from standard sources. 
Cell-Culture 
HEK-293 were maintained in Dulbecco's Modified Eagles Medium containing 10% 
Hyclone fetal bovine serum, 1 % penicillin 10,000 units/mL, 1 % streptomycin 10,000 
J.lg/mL; IX low glucose, L-glutamine, and 110 mg/L sodium pyruvate, pyridoxine 
hydrochloride at 37°C in 5.0% C02/95% air. Cells were passaged every 48 hours in T25 
flasks when reaching 80% confluency. 
Transfection and Transient Expression 
HEK-293 cells were plated at 100,000 cells/well on 1 % Poly-D-Lysine treated 24-well 
tissue culture plates a day before transfection for 5-HT uptake and 200,000 cells/well on 
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12-well tissue culture plates a day before transfection for co-immunoprecipitation and 
western blotting. Cells were transfected with hSERT plasm ids, the empty vector pcDNA3, 
and/or other experimental DNAs (as indicated in figures), up to O.8Jlg total, using Lipofectamine 
(Invitrogen) transfection reagent according to the manufacturer's protocols with Optimem cell 
culture media antibiotic-free. Where indicated, cells were treated with different modulators as 
described after 48h of transfection. 
Site-Directed Mutagenesis 
Threonine and Serine residues in hSERT intracellular domains were mutated to alanine or 
aspartic acid residues using the QuikChange site-directed mutagenesis kit (Stratagene). 
XhoIlAgeI or XbaI/AgeI fragments containing the mutated site(s) were then ligated into 
correspondingly cut wild-type hSERT. Mutations were then confirmed by nucleic acid 
sequencing the DNAs on both strands at the Medical University of South Carolina DNA 
Sequence Facility. 
SERT Activity (5-HT Uptake Assal:) 
For uptake studies, SERT-transfected HEK-293 cells were plated at 100,000 cells/well in 
12-well plates, 3 days before experiments. At assay, the medium was removed by 
aspiration, and cells were washed with 1 ml of Krebs-Ringer's-HEPES (KRH) medium 
containing (in mM): 130 NaCI, 1.3 KCL, 2.2 CaCl2, 1.2 MgS04, 1.2 KH2P04, 10 
HEPES, pH 7.4. The wash was then removed and the cells were reincubated in KRH 
containing 1.8 gmlL glucose, 100~M pargyline, and 100~M ascorbic acid ("assay 
buffer") for 5 minutes. PKG activator 8-Br-cGMP (Sigma) at 2.5mM was then added to 
half the cells while "assay buffer" was used as a vehicle control. Cells were then placed 
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in an incubator at 37°C in 5.0% C02/95% air for 30 minutes. Plates were then removed 
from the incubator and 5-HT transport assays (15 min at room temperature, added to each 
well at 10 second intervals) were initiated by the addition of eH]5-HT (5-hydroxy-eH] 
tryptamine trifluoroacetate --100 Ci/mmol. Assays were then terminated by three rapid 
washes of 37°C KRH containing 1 JlM imipramine at 10 second intervals. Imipramine, as 
a SERT antagonist, was used to block 5-HT uptake by SERT. Cells were then lysed in 
National Diagnostics Ecoscint cocktail and accumulated radioactivity directly quantified 
in a mircroplate liquid scintillation counter. During inhibitor studies, PKG inhibitor Rp-
8-pcPT-cGMPs was added 30 minutes prior to incubation with 8-Br-cGMP. Activation 
of PKC by ~-PMA was initiated by pre-incubating HEK-293 cells with 10 JlM B-PMA 
for 30 minutes at 37°C. Inhibition of PKC by Staurosporine was initiated by pre-
incubating HEK-293 cells with 10 JlM Staurosporine for 30 minutes at 37°C followed by 
above directions for 5-HT uptake. 
Nickel-Column Chromatography 
For Nickel-Column studies, HEK-293 cells (transfected with HIS-tagged and HA-tagged 
SERT) were seeded on poly-D-Iysine-coated 12-well plates at 2.5 x 105 cells/well. After 
48 h, cells were washed one time with Kreb's-Ringer-Hepes Buffer (described above) 
and then incubated with 500 JlI lysis buffer (IX PBS, IX Triton-X, and protease 
inhibitors; 1 Jlg/ml aprotinin, I Jlg/ml leupeptin, 1 JlM pepstatin, and 250JlM 
phenylmethylsulfonyl fluoride for I hr at 4°C. Samples were then collected, syringed up 
and down 4 times, and spun at 25,000 x g for 30 min at 4°C and supernatant was removed 
and collected for total fraction. Supernatant was then incubated with 100 JlI Ni-NT A 
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agarose coated beads (Qiagen) and rotated at RT for 1 hr. Slurry was then spun at 10,000 
x g for 10 minutes and the unbound fraction was collected. Remaining beads were then 
washed three times with lysis buffer with spins at 10,000 x g for 5 minutes between 
washes at 4°C. After last wash beads were eluted with 50 flilysis buffer + 10mM EOTA 
and rotated end-over-end for 20 min at RT. Beads were then spun at 10,000 x g for 10 
min. at 4°C and supernatant removed for bound fraction. 10 III of Laemmli sample buffer 
(62.5mM Tris-HCI, pH 6.8, 20% glycerol, 2% SOS, 5% ~-mercaptoethanol, and 0.01 % 
bromphenol blue) is added to each collected sample, incubated for 30 min at RT, and then 
resolved by SDS-PAGE (100/0), probed with specific antibodies as indicated in the figure 
and legends and visualized by chemiluminescence (ECL plus). 
Immunoblotting 
SERT immunoprecipitations and immunoblotting were perfonned on transfected HEK-
293 cells. Protein samples were subjected to 4-15% linear gradient SOS-P AGE, blotted 
to polyvinylidene difluoride membrane, and probed with specific antibodies as indicated 
in figures and legends. Immunoreactive bands were visualized by chemiluminescence 
(ECL reagent). Multiple exposures of blots were obtained to ensure the development 
within the linear range of the film. Band intensities were quantified using NIH Image 
(version 1.6). 
Statistics 
Unless indicated otherwise, experiments were conducted in triplicate and the mean values 
± S.E.M. from three independent experiments are compounded to form statistical 
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conclusions. Student's t test was performed for paired observations. A value of P<O.05 
is considered statistically significant. 
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Chapter III. RESUL TS 
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3.1 Aim 1: Does Protein Kinase Activation Regulate SERT Oligomerization? 
Protein kinases that stimulate SERT activity in HEK-293 cells decrease SERT 
oligomerization: Understanding that activation ofPKG by cGMP analogs increased 5-HT 
uptake we sought to see if activation of PKG had an effect on SERT oligomerization. 
There have been no studies preferred on SERT that show if phosphorylation has an effect 
on structure of the transporter. Therefore we chose Ni2+ affinity chromatography to 
assess SERT oligomerization after activation ofPKG. We chose to use HEK-293 cells 
because they appeared to contain less non-significant proteins that were recognized by 
our HA-antibody than eHG cells as was used in our previous work (data not shown). 
We first looked at the specificity of our antibodies to detect Influenza derived 
HA-antibody and HIS-antibody after Ni2+ chromatography. Plasmid expression vectors 
were created containing SERT with either a 6-His antibody epitope tag (HIS: HHHHHH) 
or a small portion of the Influenze A Virus Hemagglutin coat protein (HA: 
YPYDVPKYA) directly after the ATG start codon ofSERT both of which are easily 
recognizable by HIS and HA antibodies, respectively. We therefore transfected HEK-
293 cells with one of five conditions: (in order Lanes 1-5), Non-transfected, wild-type 
SERT with no antibody tag (WT-SERT-NT), HIS-wild-type SERT (HIS-WT-SERT), 
HA-wild-type SERT (HA-WT-SERT), and co-transfection ofHIS-WT-SERT + HA-WT-
SERT. Fig 1-1 shows that probing the total fraction for HA-antibody revealed presence 
ofHA-tagged SERT in both the HA-WT-SERT and the co-transfected HIS-WT-SERT + 
HA-WT-SERT condition but not in remaining lanes. Probing for HA-antibody in the 
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Fig. 1-1). HA- and His- Antibody specificity in HEK-293 cells. HEK-293 cells 
were transfected is plasmid expression vectors as indicated. After 48-hrs post-
transfection cells were exposed to Ni2+ affinity chromatography as described 
under "Materials and Methods". A representative immunoblot of three separate 
experiments showed that Ni2+ column beads were specific for HIS-tagged 
SERT proteins. (HIS-WT-SERT) HA-tagged WT SERT (HA-WT-SERT) is 
present in only the condition where it was co-transfected with HIS-WT-SERT 
conferring sensitivity and accuracy of the Ni2+ affinity chromatography 
technique. 
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bound fraction only revealed HA-SERT in the co-transfected lane, showing that the Ni2+ 
column affinity chromatography was sufficient for detecting the presence of HA-tagged 
SERT after co-ip and is a reliable measure for studying oligomerization of SERT. Lastly, 
reprobing of the membrane with 6-His antibody revealed HIS-tagged proteins in both the 
HIS-WT-SERT and the co-transfected lanes. Therefore from this data we can conclude 
that our antibodies and our techniques are specific. 
Our first task was to look at the stimulatory kinase, PKG and its effect on SERT 
oligomerization. HEK-293 cells were seeded as discussed in "t\1aterials and Methods" 
and 24 hours later, transfected with His6-SERT-pcDNA3 + HA-SERT-pcDNA3 in 
conjunction with either PKG or Mutant Protein Kinase G (MutPKG). MutPKG has a 
mutation at the ATP binding site that does not allow it to bind SERT. 48-hours post-
transfection cells were treated with 8-Br-cGMP for 10 minutes at 37°C and then lysed 
and assessed for [3H]5-HT uptake and oligomerization. Fig. 1-2 shows that cells 
transfected with PKG and treated with cGMP experienced an increase in SERT uptake 
compared to MutPKG transfected HEK-293 cells as we had previously seen in our 
synaptosomal and CHO-1 cell studies. Interestingly, Fig. 1-3 shows that activation of 
PKG by 8-Br-cGMP, while having an effect on increasing SERT uptake, appears to 
decrease SERT oligomerization as observed in the Ni2+ co-immunoprecipitation (Lane 2) 
compared to no significant change in oligomerization as seen in the MutPKG control 
(Lane 4). 
Since we found that PKG stimulation by 8-Br-cGMP increased uptake and 
decreased SERT oligomerization we looked at p38 MAPK, another kinase that has also 
been found to stimulate 5-HT uptake by SERT. Therefore, we co-transfected MKK3, the 
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Fig. 1-2) Effect of PKG phosphorylation on SERT 5-HT uptake. HEK-293 cells 
were transfected with expression plasmids as indicated. After 48-hrs. post-
transfection, cells were washed once with KRH Buffer and pre-treated with 8-Br-
cGMP (250 JlM) for 10 minutes at 37°C. Nickel-affinity chromatography was 
performed to study SERT oligomerization as "Materials and Methods". (AJ SERT 
Immunoblot. HEK-293 cells transfected with PKG showed a decrease in 
oligomerization in the bound fraction compared to little change to cells 
transfected with Mutant PKG (*p<O.05). (BJ Quantitative analysis of SERT 
band densities. SERT band proteins were quantified with NIH Image J, and the 
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Fig. 1-3) Effect of PKG phosphorylation on SERT oligomerization. HEK-293 
cells were transfected with expression plasmids as indicated. After 48-hrs. post-
transfection, cells were washed once with KRH Buffer and pre-treated with 8-Br-
cGMP (250 ~M) for 10 minutes at 37°C. Nickel-affinity chromatography was 
performed to study SERT oligomerization as "Materials and Methods". (A) SERT 
Immunoblot. HEK-293 cells transfected with PKG showed a decrease in 
oligomerization in the bound fraction compared to little change to cells 
transfected with Mutant PKG (*p<O.05). (B) Quantitative analysis ofSERT band 
densities. SERT band proteins were quantified with NIH Image J, and the 
densities of SERT from three separate experiments are presented as mean ± 
S.E.M. 
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constitutively active form of MAP Kinase Kinase (MEK), the upstream kinase from p38 
MAPK, with HA-tagged wild-type SERT into HEK-293 cells for 48 hrs and assessed the 
cells for eH]5-HT uptake (Fig. 1-4). It was found that co-transfection with MKK3 
caused SERT activity to increase by about 50% compared to wild-type SERT co-
transfected with pcDNA3. However when we incubated transfected cells with the p38 
MAPK inhibitor PD169316, it blocked the ability ofMKK3 to increase SERT uptake of 
5-HT (Fig 1-4). Thus stimulation ofp38 MAPK appears to increase SERT activity. 
Next, we sought to see ifp38 MAPK had a similar effect as PKG on decreasing SERT 
oligomerization. Once again we transfected HEK-293 cells with the same conditions as 
in Figure 1-4 and performed Ni2+ affinity chromatography with the celllysates. Figure 1-
5 shows that as with activation ofPKG, activation ofp38 MAPK by MKK3 caused a 
decrease in SERT oligomerization that could be blocked by pre-incubation with the p38 
MAPK inhibitor PD169316. It was also seen that pre-incubation of the control condition 
(HA-WT-SERT + HIS-WT-SERT + pcDNA3) with PD169316 caused an increase in 
SERT oligomerization greater than the basal level of oligomerization. Since it has been 
proposed that p38 MAPK basally phosphorylates SERT (Samuvel, Jayanthi et al. 2005), 
it is possible that basal phosphorylation maintains a certain endogenous state of 
oligomerization. 
Conversely, PKC decreases SERT uptake while increasing SERT oligomerization: 
It has been previously shown that activation ofPKC with phorbol esters (fJ-PMA) or 
inhibition of protein phosphatases PPI/PP2A with okadaic acid decreases SERT uptake 
(Ramamoorthy, Giovanetti et al. 1998). Therefore we decided to see ifHA- and HIS-







Fig. 1-4) Effect of MKK3 and PD169316 (a p38 MAPK inhibitor) on 5-HT 
uptake by SERT HEK-293 cells were transfected with expression plasmids as 
indicated. After 48-hrs post-transfection, 5-HT uptake was assessed as described 
under "Materials and Methods". HEK-293 cells expressing MKK3 experience 
increased 5-HT uptake as compared to cells pre-treated with 10 JlM PD169316 
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Fig. 1-5) Effect ofp38 MAPKphosphorylation on SERT oligomerization. HEK-
293 cells were transfected with expression plasmids as indicated. After 48-hrs. 
post-transfection cells lysates were exposed to nickel-affinity chromatography 
beads and assessed SER T oligomerization as described in "Materials and 
Methods". (A) SERT Immunoblot. SERT oligomerization decreased in 
experiments where MKK3 transfection was present and could be blocked by pre-
incubation of 10 JlM PD169316 for 30 min at 37°C (*p<O.05). Interestingly, 
PD169316 also had an effect on increasing SERT oligomerization (*p<O.05). 
(B) Quantitative analysis of SERT band densities. Bound extract from SERT 
were quantified using NIH ImageJ. The densities of the SERT band from three 
separate experiments are presented as mean ± S.E.M. Student's t test was used to 
anal yze data. 
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exposed to phorbol ester treatment. Figure 1-6 shows that either HA -WT -SER T or HIS-
WT-SERT, when co-incubated with ~-PMA, showed a decrease in SERT uptake of 
eH]5-HT. This effect could be blocked by the PKC inhibitor staurosporine. 
Staurosporine itself appeared to have no effect on 5-HT uptake by SERT (Fig. 1-6). 
Seeing a decrease in SER T activity we were interested to see if there was an effect on 
oligomerization of SERT by activation of PKC. Surprisingly, Figure 1-7 shows that 
activation ofPKC by ~-PMA creates an increase in SERT oligomerization. This effect 
could be blocked by pre-incubation of the PKC inhibitor staurosporine. 
There are three possible methods to rapidly regulating transport of 5-HT 
molecules across the plasma membrane: (1) regulation of the open probability of the 
transporter, (2) regulation of the permeability of the transporter .. and (3) regulation of the 
number of transporters available at the plasma membrane surface for 5-HT translocation. 
Our previous work has shown that PKG regulates changes in the rate of 5-HT 
translocation by increasing the V max of the transporter upon phosphorylation while not 
changing affinity or Km of 5-HT for SERT (Ramamoorthy, Samuvel et al. 2007). Other 
work has shown that activation ofPKC increases SERT endocytosis and decrease SERT 
uptake of 5-HT (Ramamoorthy, Giovanetti et al. 1998). Therefore, it is possible that 
different kinases that act on different phosphorylation sites throughout SERT (e.g. PKG 
-7 T276) affect oligomerization that causes changes in one or more of the above three 
possibilities. For example it is possible that phosphorylation of SERT by PKC causes 
previously unexposed oligomerization sites to be exposed and cause and increase in 
oligomerization. This change in oligomerization may be a signal for the recruitment of 
endocytotic machinery involved in the internalization of SERT from the plasma 
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membrane. Conversely, activation ofPKG may decrease SERT oligomerization and 
subsequently allow the recycling rate of the transporter (the rate at which the transporter 
resets to accept more ligand) to increase causing a greater influx of 5-HT than if SERT 
had not been phosphorylated at all. More work understanding SERT binding protein 
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Fig. 1-6) Effect of {J-PMA and staurosporine on SERT uptake in HEK-293 cells. 
(AJ HEK-293 cells were transfected with HA-WT SERT as indicated. After 48-
hrs post-transfection, cells were washed once with KRH buffer and treated with 
~-PMA for 30 min at 37°C. 15 minutes into ~-PMA treatment, cells were either 
given staurosporine (a PKC inhibitor) or vehicle assay buffer. HEK-cells were 
the assayed for 5-HT uptake as described under "Materials and Methods". (BJ 
HEK-293 cells were treated the same as in (AJ but HIS-WT SERT was 
transfected instead of HA-WT SERT and the same protocol was used as in (AJ. 
Both studies revealed that treatment with ~-PMA for 30 minutes decreased SERT 
uptake of 5-HT, (*p<0.03). However pre-incubation of staurosporine, blocked 
~-PMA's effect of decreasing uptake of 5-HT by SERT. Staurosporine itself had 
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Fig. 1-7) Effect of fJ-P MA and subsequent activation of P KC on SERT 
oligomerization. (AJ SERT Immunoblot. HEK-293 cells were pre-treated with or 
without ~-PMA for 30 min at 37°C. At 15 minutes post-~-PMA incubation cells 
were treated with either staurosporine or assay buffer for the remaining 15 
minutes. Cells were then exposed to Ni-NTA Superflow affinity 
chromatography as described under "Materials and Methods". Results show (AJ 
incubation with ~-PMA increase SERT oligomerization (*p<0.03) while this 
effect can be blocked with co-incubation of staurosporine. Staurosporine itself 
had no effect on SERT oligomerization. (BJ Quantitative analysis ofSERT band 
densities. Ni2+ affinity chromatography of SERT proteins was quantified by NIH 
ImageJ, and the densities of SERT bands from three independent and separate 
experiments are represented as mean ± S .E.M. * indicates significant differences 
compared to vehicle (*p<O. 05) by student's t test. 
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3.2 Aim 2: Is SERT Phosphorylation Required For Regulation of SERT 
Oligomerization? 
Mutations at the PKG phosphorylation site, Thr276, mimic activation ofPKG by 
8-Br-cGMP: We have previously shown that PKG phosphorylates SERT at Thr276 
(Ramamoorthy, Samuvel et al. 2007) and that this effect is trafficking-independent. 
Therefore we were curious to see if mutations at this site had an effect on SERT 
oligomerization. We used site-directed mutagenesis to generate alanine (T276A) and 
aspartic acid (T276D) polymorphisms at Thr276. We have previously shown that T276A 
blocks the effect of increasing SERT activity by cell permeable cGMP analogs and that 
the T276D mutation mimics the cGMP effect alone and further stimulation by 8-Br-
cGMP is not possible (Ramamoorthy, Samuvel et al. 2007). Therefore we co-expressed 
WT-SERT with varying concentrations of empty vector pcDNA3, T276A-SERT, or 
T276D-SERT. Figure 2-1A shows that increasing amounts ofT276D co-transfected with 
consistent amounts of wild-type SERT showed increased uptake compared to control 
conditions (WT-SERT + pcDNA3). This effect was not present in co-transfections of 
WT-SERT + T276A (Fig 2-1B). To make sure that our HIS- and HA-tagged SERT 
worked in the same fashion as untagged mutants we performed the same experiment 
using HA- and His6-SERT. Figure 2-2A and 2-2B show that HIS- and HA-SERT 
perform similar levels of uptake as untagged SERT, respectively. 
Therefore understanding that SERT activity is increased by mutation to aspartic 
acid, T276D, and is not altered when mutated to alanine T276A we used these mutations 
as a tool to look at SERT oligomerization when SERT is in a mimicked state of 
phosphorylation or when SERT cannot be phosphorylated by PKG, respectively. The 
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Fig. 2-1) Effect of co-transfection of SERT mutants with wild-type SERT in HEK-
293 cells. HEK-293 cells were transfected with expression plasmids as 
indicated. After 48-hrs post-transfection, 5-HT uptake was assessed as described 
under "Materials and Methods". (A) (*p<0.05) indicates significant differences 
between wild-type SERT plus empty expression vector pcDNA3 and wild-type 
SERT plus mutant T276D SERT. (B) This effect was not present in the 
condition using T276A SERT in place of T276D SERT. Student's t test was 
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Fig. 2-2) Effect of co-transfection of HA-or HIS- tagged SERT mutants with HA-
or HIS-tagged wild-type SERT. HEK-293 cells were transfected with expression 
plasmids as indicated. After 48-hrs. post-transfection, 5-HT uptake was assessed 
as described under "Materials and Methods". (A) (*p<0.05) indicates significant 
differences between HIS-tagged wild-type SERT plus empty vector pcDNA3 and 
HIS-tagged wild-type SERT plus HIS-tagged mutant T276D SERT. (B) 
(*p<0.05) indicates significant differences between HA-tagged wild-type SERT 
plus empty vector pcDNA3 and HA-tagged wild-type SERT plus HA-tagged 
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Fig. 2-3) Effect of site-directed mutagenesis SERT mutants at Thr276 results in 
decreased SERT oligomerization. (A) SERT immunoblot. HEK-293 cells were 
transfected with HIS-WT and one of three conditions (HA-WT, HA-T276A, and 
HA-T276D) as shown. Cells were also transfected with pcDNA3 + HA-WT as a 
negative control (last lane). Results show that co-transfection of HIS-WT SERT 
+ HA-T276D results in a decrease in oligomerization some but not significant 
change was seen in the condition HIS-WT SERT + HA-T276A. (B) Quantitative 
analysis of SERT band densities. Ni2+ affinity chromatography of SERT proteins 
was quantified by NIH ImageJ, and the densities of SERT bands from three 
independent and separate experiments are represented as mean ± S.E.M. * 
indicates significant differences compared to vehicle (*p<O. 05) and (*p <O. 01) by 
student's t test. 
SERT oligomerization much as the data seen in Figure 1-3. It is important to note that 
while co-transfection ofT276A SERT with WT-SERT caused no increase in SERT 
uptake (Fig 2-1) it still appeared to cause a slightly significant decrease in SER T 
oligomerization compared to wild-type control. To address the ability of the constructed 
SERT mutants to form oligomers themselves, we transfected varying combinations of 
HIS-WT-SERT, HA-WT-SERT, HIS-T276D-SERT, and HA-T276D-SERT as shown in 
Figure 2-4. Oligomerization of SERT is decreased regardless of the tag of mutation (both 
His6-T276D and HA-T276D SERT show decreased oligomerization at approximately the 
same expression level (Fig. 2-4) ruling out any artifact that may have been being caused 
by the antibody tag, and interestingly, SERT is still able to form an oligomer when both 
mutant conditions are transfected together (HIS-T276D-SERT + HA-T276D-SERT). 
This finding suggests that mutations that mimic phosphorylation of SER T by PKG 
(T276D) also show the same pattern of decreased SERT oligomerization. Furthermore, 
the ability ofHIS-T276D-SERT and HA-T276D-SERT to form an oligomer raises the 
question as to the quaternary structure ofSERT. We have shown that p38 MAPK 
activation phosphorylates SERT at T276 and another unknown putative phosphorylation 
site (unpublished results). Therefore we looked to see if mutation at Thr276 to alanine 
could block the decrease in oligomerization that was found when HEK-293 cells were co-
transfected with wild-type SERT and the constitutively active upstream kinase ofp38 
MAPK, MKK3. Figure 2-5 shows that while MKK3 does decrease SER T 
oligomerization (as seen in Figure 2-5A) this effect is not blocked by co-transfection of 
the inert T276A, leaving the possibility that other phosphorylation sites may be 
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Fig. 2-4) SERT is able to form oligomers higher in quarternary structure than 
monomers. (A) SERT Immunoblot. HEK-293 cells were transfected with 
expression plasmids as shown. T276D constructs (HA- and HIS-) when co-
transfected with the corresponding wild-type SERT both showed decreases in 
SERT oligomerization. However, when both constructs were co-transfected 
together (Lane D) a band was still present signifying that SERT is able to create 
structures of higher order than monomers. (B) Quantitative analysis of SERT 
band densities. Ni2+ affinity chromatography of SERT proteins was quantified by 
NIH ImageJ, and the densities of SERT bands from three independent and 
separate experiments are represented as mean ± S .E.M. * indicates significant 
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Fig. 2-5) Effect of T2 76A 's ability to block decrease in oligomerization by 
MKK3. (A) SERT immunoblot. HEK-293 cells were transfected with expression 
plasmids as shown. Lane A) HIS-WT + HA-WT + pcDNA3, Lane B) HIS-WT + 
HA-WT + MKK3 , Lane C) HIS-WT + HA-T276A + pcDNA3, Lane D) HIS-WT 
+ HA-T276A + MKK3. Co-transfection ofMKK3 with wild-type SERT showed 
a decrease in SERT oligomerization as in Figure 5. Cooctransfection of MKK3 
with HA-T276A (shown before not to provide a significant decrease in SERT 
oligomerization) did not block or reverse the effect of MKK3 ,on SERT 
oligomerization. (B) Quantitative analysis of SERT band densities. Ni2+ affinity 
chromatography of SERT proteins was quantified by NIH ImageJ, and the 
densities of SERT bands from three independent and separate experiments are 
represented as mean ± S.E.M. * indicates significant differences compared to 
vehicle (*p<O. 01) by student's t test. 
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3.4 Aim 3: Do Human SERT Variants That are Resistant to PKG and p38 
MAPK Regulation Affect SERT Oligomerization? 
Human mutant polymorphisms at Is0425(V) and Gly56(A) also appear to affect 
oligomerization in the same fashion as kinases that increase SERT activity (P KG and p38 
MAPK): Previously, human mutations at I425V and G56A that have been found in 
patients that suffer from obsessive-compulsive disorder, appear to increase SERT activity 
with no further stimulation by PKG agonists. Therefore, we sought to distinguish if these 
polymorphisms appeared to also have an effect on SERT oligomerization. In figure 3-1, 
HEK-293 cells were transfected with expression plasmids as shown in the picture and 
incubated with 8-Br-cGMP as described above. The control condition (HIS-WT-SERT + 
HA-WT-SERT) is in agreement with our previous data with respect to 8-Br-cGMP, but 
interestingly, co-incubation ofHIS-WT-SERT + HA-I425V-SERT revealed decreased 
oligomerization on its own with no further decrease in oligomerization with 8-Br-cGMP 
incubation. It has been shown that mutation ofT276 to alanine (T276A) blocks the 
ability of I425V to increase SERT uptake of 5-HT (Zhang and Rudnick 2005), however 
our data show that the double mutant (HA-I425V/T276A) co-transfected with HIS-WT-
SER T showed the same decrease in the single mutant condition in oligomerization with 
or without PKG activation by 8-Br-cGMP. 
G56A is another human polymorphism that has been associated with obsessive-
compulsive disorder and increased 5-HT uptake by SERT. Therefore we performed the 
experiments as in Figure 3-1 and assessed the oligomerization state of SERI. Much like 
Fig. 3-1, incubation of the wild-type condition with 8-Br-cGMP caused a decrease in 
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Fig. 3-1) Effect of human mutant polymorphism 1425 V on SERT oligomerization. 
(A) SERT Immunoblot. HEK-293 cells were transfected with expression 
plasmids as shown. Cells were washed once with KRH buffer and then pre-
incubated with or without 8-Br-cGMP (250 JlM) for 10 minutes at 37°C. Cells 
were then exposed to Ni2+ affinity chromatography and assayed by SDS-PAGE. 
As quantitated in (B) , treatment of wild-type SERT with cGMP resulted in a 
decrease in SERT oligomerization as similar to Figure 1-3. Interestingly, co-
transfection with I425V results in a similar decrease as wild-type SERT + cGMP 
but no further decrease was seen when this condition was further exposed to 8-
Br-cGMP. Also co-transfection of HIS-WT-SERT + the double mutant HA-
I425V/T276A did not block the human polymorphisms ability to decrease SERT 
uptake without cGMP, which also had no further effect (*p<O.05). 
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Fig. 3-2) Effect of human mutant polymorphism G56A on SERT oligomerization. 
(A) SERT Immunoblot. HEK-293 cells were transfected with expression 
plasmids as shown. Cells were washed once with KRH buffer and then pre-
incubated with or without 8-Br-cGMP (250 ~M) for 10 minutes at 37°C. Cells 
were then exposed to Ni2+ affinity chromatography and assayed by SDS-PAGE. 
As quantitated in (B), treatment of wild-type SERT \vith cGMP resulted in a 
decrease in SERT oligomerization as similar to Figure 1-4. Interestingly, co-
transfection with G56A results in a similar decrease as wild-type SERT + cGMP, 
(*p<0.05). The double mutant HA-G56A1I425V SERT co-transfected with HIS-
WT-SERT also showed a decrease in SERT oligomerization. Interestingly, 
treatment of either condition with 8-Br-cGMP resulted in a further decrease in 
SERT oligomerization (**p<0.03). 
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WT -SER T caused a decrease in SER T oligomerization. However unlike experiments 
with 1425V, Ni2+ affinity chromatography experiments with G56A revealed an additional 
decrease in oligomerization when incubated with 8-Br-cGMP for 10 min at 37°C. The 
double mutant (G56A1T276A) is similar to 1425V/T276A in that it does not block the 
decrease in oligomerization either, but in fact shows a further decrease in oligomerization 
when treated with 8-Br-cGMP (Fig. 3-2). 
Proper oligomerization ofSERT is necessary for SERT exportationfrom the ER. 
It has been proposed that monoamine transporter oligomerization is necessary for ER 
exportation. Therefore, we wanted to confirm if indeed co-expression of varying SERT 
proteins (HA-WT-SERT, HIS-WT-SERT) do indeed only form oligomers if co-
transfected in HEK-293 cells. We transfected cells with the two variants together in the 
same well (co-transfected) or in different wells and mixed the two together before 
experimentation. The results in Figure 3-3 show that co-transfection ofHIS-WT-SERT + 
HA-WT-SERT showed a band in the bound fraction while the condition in which HIS-
WT-SERT and HA-WT-SERT were transfected separately and the mixed showed no 
band in its corresponding lane. Therefore it is possible that since HA-epitope tags cannot 
bind to Ni2+ chromatography beads that SERT oligomers are only created by proper 
folding, glycosylation, and complexing in the ER and the Golgi complex. 
Effect of the drug of abuse, cocaine, on SERT oligomerization. Cocaine has been 
shown to block not only SERT but other monoamine transporters as well such as DAT 
and NET (Farde, Halldin et al. 1994; Miller, Yatin et al. 2001). Blocking SERT by 
cocaine treatment causes a decrease in SERT's ability to perform 5-HT uptake. 
Therefore., we chose a range of concentrations of cocaine that ranged from 0-50 JlM. 
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Fig. 3-3) Oligomerization of SERT only occurs when protein is properly 
packaged in the endoplasmic reticulum. (A) SERT Immunoblot. HEK-293 cells 
were transfected with expression plasmids as shown. Lane A) HIS-WT-SERT + 
HA-WT-SERT (co-transfected), Lane B) HIS-WT-SERT + HA-I425V 
(transfected in separate wells and then lysates mixed). After 48-hrs post-
transfection cells were lysed and exposed to Ni2+ affinity chromatography. 
Immunoblotting revealed that co-transfection of HIS-WT-SERT with HA-WT-
SERT (Lane A) results in oligomerization of the SERT proteins. Lysates in Lane 
B were mixed and show that no band is present in the bound fraction. (B) shows 
graphical representation of immunoblot (A). 
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HEK-293 cells were transfected with HIS-WT-SERT + HA-Wl~ ... SERT and 48 hrs pre-
incubated with the range of cocaine concentrations listed above for 30 minutes at 37°C 
before assayed by Ni2+ affinity chromatography. Ni2+ Co-immunoprecipitation 
experiments, in figure 3-4, revealed a response to cocaine treatment in a typical bell-
shaped curve with the highest and only significant finding at the 7.5 JlM cocaine 
concentration (---50% increase in SERT oligomerization compared to no cocaine 
treatment [0 JlM]). This result requires further study as this is the first time it has been 
reported that, in addition to protein kinases affecting SERT oligomerization, drugs of 
abuse affect SERT oligomerization. Therefore, oligomerization of SERT may have some 
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Fig. 3-4) Cocaine appears to increase SERT oligomerization in HEK-293 cells. 
(AJ SERT Immunoblot. HEK-293 cells were transfected with HIS-WT SERT + 
HA-WT SERT expression plasmids. 48-hrs post-transfection cells were treated 
with a varying range of cocaine concentrations [0-50 J.lM] for 30 min at 37°C and 
exposed to Ni2+ affinity chromatography. Results show that there was an 
increase in SERT oligomerization at the 7.5 J.lM concentration of cocaine. (B) 
Quantitative Analysis of SERT band densities. SERT bands were quantitated 
using NIH ImageJ, and the densities of SERT bands from three independent 
experiments are presented as mean ± S.E.M. (*p<O.05). 
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Chapter IV. DISCUSSION 
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In this study we have further studied the role of phosphorylation not only on 
SERT uptake and surface expression but also on oligomerization of SERT in HEK-293 
cells. The main conclusions from the studies reveal that SERT exists in HEK-293 as an 
oligomer and can be affected and manipulated by cellular changes. The first piece of 
evidence that supports this theory is that stimulation of various common cellular kinases 
known to interact with SER T affect oligomerization as witnessed through Ni2+ affinity 
chromatography. Second, we have provided evidence that mutation of the known PKG 
phosphorylation site, Thr276, mimics PKG effects on SERT oligomerization. Third, we 
have also shown that human mutant polymorphisms that are found in disease such as 
,oeD and autism, respectively, appear to also affect oligomerization of SERT and that co-
expression of human mutant polymorphisms with wild-type SERT are necessary for 
oligomerization. Lastly, drugs of abuse such as cocaine appear to affect the topological 
structure of SERT oligomerization. 
First we found that activation of protein kinases (PKG and p38 MAPK) that 
appear to have a stimulatory effect on SERT activity decrease SERT oligomerization. 
Previous findings have indicated that stimulation of histamine (Launay, Bondoux et al. 
1994), adenosine A3 receptors (Miller and Hoffman 1994), nitric oxide synthase (Zhu, 
Hewlett et al. 2004), and activation of protein kinases with cell-permeable analogs 
activate the PKG pathway and increase SERT activity and suggested that this stimulatory 
effect occurs through a change in V max but not Km (Ramamoorthy, Samuvel et aI. 2007). 
It is possible that phosphorylation of SERT causes an uncoupling of the aforementioned 
methods of creating SER T oligomerization. The change in V max by PKG phosphorylation 
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as mentioned above may be a direct result of the change in oligomerization state of the 
transporter after phosphorylation. It is possible that lower quarternary structures of 
SERT (i.e. the monomer) may translocate 5-HT more rapidly than higher homo-
oligomeric structures. It may also be that during this time while SERT is "de-
oligomerized" it may have the opportunity to bind with known pre-synaptic proteins. 
One of these proteins in particular is a neuronal SNARE (soluble N-ethylmaleimide-
sensitive factor-attachment protein receptor) protein syntaxin-IA (SynlA). SynlA is a 
pre-synaptic protein that has been found to be important for vesicle docking in the CNS 
and genetic knock-out of Syn 1 A results in a decrease in the vesicle recycling pool and the 
number of vesicles exocytosed during brief action potential trains (Ryan, Li et al. 1996), 
The SynlA protein has been shown to associate with SERT at the N-terminal (Haase 
2001; J. Haase 2001; Sung, Apparsundaram et al. 2003) and in lIpid raft fractions in 
HEK-293 cells and rat brain homogenate (Muller, Wiborg et al. 2006). Experiments 
performed have shown that cleavage ofSynlA with botulinum toxin Cl decreases 5-HT 
function by decreasing transport capacity without changing the affinity of 5-HT for SERT 
(Quick 2002). Also, interaction of SynlA with SERT has shown to be decreased by 
activation ofPKC (Haase 2001; 1. Haase 2001; Quick 2002) and inhibition ofp38 MAPK 
with the inhibitor PD169316 (Samuvel, Jayanthi et al. 2005). It is therefore possible that 
activation of the PKG pathway causes directly or indirectly a decrease in SERT 
oligomerization, greater SynlA-SERT association, and an increase in 5-HT uptake 
activity. Since SynlA has been found to bind to the N-terminal ofSERT and appears to 
be the mechanism of association for these proteins, it is possible that the "de-
oligomerization" of SERT exposes sites within the N-terminal that make SynlA more 
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readily able to bind SERT. Since disruption of SynlA-SERT binding decreases SERT 
5-HT uptake it is feasible to predict that a phosphorylation path,vay that decreases 
oligomerization actually increases SERT activity by increasing SynlA-SERT interaction 
or a similar protein necessary for vesicle fusion. Further studies need to be performed 
looking at co-immunoprecipitation changes in association of SERT-SynlA andlor SERT 
and other binding proteins. 
Since it has been shown that p38 MAPK appears to be an intermediate step in the 
PKG pathway, (Zhu, Carneiro et al. 2005) responsible for increases in 5-HT uptake in 
heterologous cell systems, and inhibition ofp38 MAPK with a MAPK inhibitors blocks 
5'rN-ethylcarboxamidoadenosine (NECA) stimulation of A3 adenosine receptors and 
downstream increases in SERT activity, (Zhu, Hewlett et al. 2004; Zhu, Carneiro et al. 
2005) we decided to explore whether or not activation ofp38 MAPK affected 
oligomerization ofSERT. p38 MAPK activation has been found to increase SERT V max 
without creating a change in SERT surface expression rendering p38 MAPK to regulate 
SERT in a trafficking-independent matter (Samuvel, Jayanthi et al. 2005). In our studies 
activation ofp38 MAPK by MKK3 increased SERT uptake and decreased SERT 
oligomerization, an effect that could be blocked by the p38 MAPK inhibitor P0169316. 
HEK-293 cells transfected with MKK3 and blocked by the p38 MAPK inhibitor 
PO 169316 expressed levels of oligomerization that were comparable to controls. 
Interestingly, incubation in the control condition of wild-type SERT with the p38 MAPK 
inhibitor PO 169316 increased oligomerization without further activation of p3 8 MAPK 
but produced no detectable change in eH]5-HT uptake. The latter data possibly point to 
the ability ofp38 MAPK to basally phosphorylate SERT in native cells. This basal 
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phosphorylation appears to be necessary for the proper insertion of SER T into the plasma 
membrane as inhibition ofp38 MAPK with PD169316 decreases SERT expression in 
surface biotinylated fractions in rat midbrain synaptosomes with a concomitant decrease 
in 5-HT uptake (Samuvel, Jayanthi et al. 2005). Basal phosphorylation of SERT is not 
controlled by PKC, Protein Kinase A (PKA), Calcium-calmodulin kinase 2 (CamK), or 
Ca2+ chelation (Ramamoorthy, Giovanetti et al. 1998). Therefore, it is possible that this 
inhibition ofp38 MAPK causes an increase in the oligomerization ofSERT that causes 
SERT to remain internalized creating a negative feedback mechanism perhaps necessary 
to control SERT uptake during times of low extracellular concentrations of 5-HT or times 
when serotonergic signaling is weaker than normal. However, p38 MAPK is 
characterized as a stress-activated protein kinase (SAPK) and has been shown to be 
activated by environmental stressors such as anisomycin, H202, UV radiation (Zhu, 
Carneiro et al. 2005), hypoxia, ischemia, ischemialreperfusion (RJ. 1994; Cano E 1995), 
and inflammatory cytokines such as Tumor Necrosis Factor Alpha (TNF-u) (Liu Z. G. 
1996). Therefore activation ofp38 MAPK by one or more of these "stressors" may cause 
an increase in plasma membrane expression of SER T, which could be necessary to gather 
extracellular 5-HT molecules that potentially could be degraded by activation of 
molecules that breakdown monoamines (i.e. inflammatory cytokines, monoamine 
oxidases, and cellular proteases). Therefore if a decrease in oligomerization is necessary 
to increase uptake in times of stress, it has fathomable that in tiines of low stress, 
oligomerization increases. Also it should be noted that it has been reported that 
inhibition ofp38 MAPK decreases SERT/SynlA association with a concomitant decrease 
in 5-HT uptake in midbrain synaptosomes (Samuvel, Jayanthi et al. 2005) adding further 
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support that SERT binding proteins may be necessary components for modifying the 
oligomerization state of SERT. 
We also saw that activation ofPKC, by the phorbol ester fJ-PMA, increased 
association of SERT homo-oligomers in HEK-293 cells. PKC activation has been found 
to decrease SERT activity by internalizing it from the plasma membrane (Ramamoorthy, 
Giovanetti et al. 1998; Ramamoorthy and Blakely 1999; Vaughan 2004). Samuvel et al 
(2005) showed that SERT was inserted into the plasma membrane by p38 MAPK and 
internalized by PKC (Samuvel, Jayanthi et al. 2005). The inhibition ofp38 MAPK by 
either siRNA constructs directed at p38 MAPK or the compound PD169316 decreased 
uptake of 5-HT by SERT but by a different mechanism than PKC. p38 MAPK inhibition 
decreased plasma membrane insertion compared to PKC's effect of increasing SERT 
endocytosis (Samuvel, Jayanthi et al. 2005). It is possible that PKC's ability to increase 
oligomerization may be an intracellular signal for increasing endocytosis of SERT. 
Support for this arises from other systems that show activation of PKC increases 
oligomerization of various proteins. For example, phosphorylation of Ezrin-Radixin-
Moesin (ERM) binding phosphoprotein 50 (EBP50), a scaffolding protein essential for 
the localization and coordinated activity of apical transporters in endothelial cells, by 
PKC increases EBP50 oligomerization (Fouassier, Nichols et al. 2005). Also, activation 
ofPKC increases oligomerization of transmembrane proteoglycan syndecan-4, which is a 
co-receptor with integrins in cytoskeleton-matrix interaction (Oh, Woods et al. 1997). 
While these studies speak to increases in oligomerization with activation of PKC, they do 
not discuss changes in activity or trafficking of the specific proteins. To our knowledge 
this is the first paper that discusses changes in oligomerization of transporters by 
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activation of protein kinases. One possible mechanism behind decreased PKC activity 
with concomitant increased oligomerization is its possible association with SERT binding 
proteins. One such protein is Secretory Carrier Membrane Protein 2 (SCAMP2) which 
has been found to associate with SERT in both rat brain tissue and transfected HEK-293 
cells and this association appears to reduce SERT activity in a trafficking-dependent 
manner (Muller, Wiborg et al. 2006). Another SERT binding protein, Hic-5 is a multiple 
LIM-domain protein previously thought to be a DAT-interacting protein found in the 
brain that is not only found in neurons, but also in platelets, an area high in 5-HT and 
SERT expression. Another possible protein that interacts with SERT is myristoylated 
alanine-rich Ckinase substrate (MacMarcks) (Jess, El Far et al. 2002). Upon PKC 
activation MacMarcks is translocated from intracellular compartments to the plasma 
membrane where it interacts with the C-terminal tail of SERT where it plays a central 
role in regulating SERT trafficking. Interestingly, interaction of SERT with MacMarcks 
upon PKC activation causes an approximate 30% decrease in 5-HT uptake compared to 
uptake with ~-PMA itself. It is possible that upon PKC activation SERT oligomerizes 
(possibly through the exposure of previously unavailable oligomerization sites), and 
binding proteins like the ones mentioned above are recruited to the plasma membrane to 
aid in internalization of SERT. Once SERT is internalized it is dephosphorylated by 
protein phosphatases PP1/PP2A (Ramamoorthy, Giovanetti et al. 1998; Bauman, 
Apparsundaram et al. 2000) which may cause these binding proteins to dissociate from 
SERT allowing SERT to either recycle back to the plasma membrane, stored in 
intracellular vesicles, or be targeted for degradation. 
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Research in receptor oligomerization adds support to the claim that 
phosphorylation can affect protein oligomerization. For example phosphorylation of 
small heat shock/alpha-crystallin proteins, heat shock proteins 23 and 70 (hsp 23 and 
hsp70, protective against cardiac ischemia damage), by stress-responsive cascades 
including MAPKAP kinase 2/3 and p38 has been shown to form smaller oligomeric 
processes compared to nonphosphorylated hsp proteins (Martin, Hickey et al. 1999; 
MacRae 2000). Also phosphorylation ofhsp25, which has been shown to be protective 
against TNFa- or H20 2-mediated cytotoxicity, by p38 MAPK also showed smaller 
oligomeric processes as above. In contrast, increased activation of PKC in painful 
diabetic neuropathy causes an increase in oligomerization of the vanilloid receptor 1 
(VRl) associated with inflammation and injury-induced pain (Hong and Wiley 2005). 
Another study showed that activation of PKC by UV stimulation of mitochondrial 
reactive oxygen species (mROS) increased translocation of Bax to mitochondria where 
oligomerization was promoted and increased apoptotic cell death in MCF-7 breast cancer 
cells (Pedram, Razandi et al. 2006). Lastly, oligomerization of AoHex 1, the major 
protein of the woronin body, a specialized peroxisome involved in septal pore sealing and 
protecting filamentous fungus from excessive cytoplasmic bleeding, increased with PKC 
activation while inhibitors of PKC, bisindolylamaleimide I and chelerythrine, resulted in 
a reduction of AoHex 1 oligomerization (Juvvadi, Maruyama et al. 2007). Interestingly 
activation of cAMP-dependent kinase (PKA) shows no change in oligomerization state of 
vasodilator-stimulated phosphoprotein (VASP) associated with promoting actin 
nucleation, a kinase that is thought to exert its effects on SERT through a long-term, 
chronic regulation of gene expression (Lawrence, Comerford et al. 2002). This may be 
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of relevance because it appears that PKA exerts its' effects on SERT in a chronic fashion 
that causes changes in SERT gene expression (Cool, Leibach et al. 1991; Ramamoorthy, 
Ramamoorthy et al. 1995). This is in direct contrast to kinases such as PKG, p38 MAPK, 
and PKC, all of which appear to exert their effects on SERT in an acute fashion, by 
regulating uptake and surface expression. This data helps support that different protein 
kinase activations can affect protein oligomerization. However, our experiments for the 
first time show these effects in the serotonin transporter. 
Since we have shown that activation ofkinases that increase SERT activity 
decrease SERT oligomerization (PKG and p38 MAPK) and activation ofkinases that 
decrease SERT activity increase SERT oligomerization, we decided to study ifSERT 
phosphorylation is necessary for SERT oligomerization. To do this we created point 
mutations at the known PKG phosphorylation site Thr276, T276A and T276D, as we 
have previously shown (Ramamoorthy, Samuvel et al. 2007). Alanine mutation at the 
site of phosphorylation (T276A) allows one to mimic a "non-phosphorylatable" 
transporter at that site and mutation to aspartic acid (T276D) theoretically creates a 
"constitutively activated" SERT. Our mutation studies revealed that mutation to either 
alanine or aspartic acid created a decrease in SERT oligomerization compared to wild-
type controls. While we expected to see the decrease in oligomerization present in the 
T276D mutant, since it mimics our earlier findings that PKG activation decreases SERT 
oligomerization, it was interesting to find that T276A also caused a decrease in 
oligomerization. There are a couple possibilities why this may have occurred. 1) It is 
possible that mutation ofThr 276 to alanine creates a structural change in SERT itself 
that does not allow the transporter to properly oligomerize. 2) Mutation to alanine causes 
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a change in the molecular forces that govern the second intracellular loop and could cause 
an effect that changes oligomerization from wild-type. 3) It is possible that T276A 
blocks partial phosphorylation of SERT but not all. Our lab has previously shown that 
basal phosphorylation of SERT can partially be contributed to constitutive 
phosphorylation by p38 MAPK (Samuvel, Jayanthi et al. 2005). Data we have collected 
(unpublished results) show that p38 MAPK phosphorylates SERT not only at Thr276 but 
at another putative phosphorylation site as well. Since we have shown here that 
activation ofp38 MAPK decreases SERT oligomerization, it may be possible that the 
phosphorylation of this site is causing the slight but significant decrease in 
oligomerization we discovered in our current experiments. p38 MAPK is endogenously 
expressed in HEK-293 cells (Nagao, Yamauchi et al. 1998; Hou, Ye et al. 2004) so it is 
feasible that this latter possibility has some merit. To support this idea we decided to co-
transfect His6-WT-SERT with either HA-WT-SERT + MKK3 or HA-T276A-SERT with 
MKK3. Here it appeared that the T276A mutation caused a slight decrease in 
oligomerization as in Figure l-SB but was not able to block the decrease in SERT 
oligomerization when it was co-transfected with MKK3, Fig 1-7. Therefore, it appears 
that p38 MAPK is not solely dependent on Thr276, at least for its oligomerization effect, 
and this may help explain why co-transfection of T276A with MKK3 does not inhibit 
decreased SERT oligomerization. This data also sheds some light to support that while 
activation ofPKG and p38 MAPK lead to increased SERT activity the mechanisms of 
how this occurs may be different. We have shown that there is no change in SERT 
trafficking upon PKG activation with 8-Br-cGMP (Ramamoorthy, Samuvel et al. 2007) 
but as previously mentioned, inhibition of p3 8 MAPK with PD 169316 decreases 
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insertion of SERT into the plasma membrane (Samuvel, J ayanthi et al. 2005). Therefore, 
the difference we experienced in oligomerization with T276A + 8-Br-cGMP in PKG and 
p38 MAPK could also possibly be contributed to SERT trafficking differences. 
We also decided to investigate the role of human polymorphisms that have been 
found in clinical screenings of patients and have been to have co-morbity with obsessive-
compulsive disorder (OCD), and to a lesser extent; Asperger's syndrome, social phobia, 
anorexia nervosa, diabetic disorders, and alcohol and other substance abuse/dependence 
(Ozaki N, * Goldman D et al. 2003) The two mutants we studied, Is0425Vai (I425V) 
and Gly56Ala (G56A) have both been shown to increase SERT uptake with no further 
increase in uptake with co-incubation of cGMP cell-permeable analogs (Kilic, Murphy et 
al. 2003). Since these mutations appear to increase SERT activity, much like activation 
ofPKG, p38 MAPK, and the SERT mutant T276D, we decided to assess I425V and 
G56A mutations with SERT association. Our results showed that HEK-293 cells co-
transfected with either HIS-WT-SERT + HA-I425V-SERT or HIS-WT-SERT + HA-
G56A-SERT both showed an endogenous decrease in SERT oligomerization as analyzed 
by Ni2+ affinity chromatography compared to wild-type controls. These results are 
similar to our earlier findings that PKG, p38 MAPK, and T276D decrease SERT 
oligomerization. However, when HEK-293 cells were transfected with human mutant 
conditions as above and treated with 8-Br-cGMP (IOflM, 15 minutes, 37°C), we observed 
a significant decrease in oligomerization in cells transfected with G56A but not with 
I425V. This is a curious finding because it has been shown previously that 8-Br-cGMP 
does not further increase 5-HT uptake in cells transfected with I425V or G56A (Kilic, 
Murphy et al. 2003). One possible explanation of these results is that mutation at these 
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sites could cause conformational changes that do not allow the PKG phosphorylation site 
T276 to be readily available to PKG for phosphorylation. However, since these two 
mutations lie on far spectrums of the SERT gene, it is possible that G56A (which lies in 
the intracellular N-terminal region of SERT) and 1425V (that resides within the fourth 
intracellular loop (IL4) between TM regions 8 and 9) may exert differing effects on the 
SERT micro-environment. It is possible that mutation at I425V creates a micro-
environment that is not able to allow phosphorylation ofT276 by PKG, while mutation at 
G56A may not cause such a change in protein conformational shape. This explanation 
may account for the lack of increased 5-HT uptake by I425V SERT as has been 
previously reported (Kilic, Murphy et al. 2003). 
N ext we looked to address the question if oligomerization of the human mutant 
polymorphism I425V is dependent on proper folding, packaging, and exportation in the 
endoplasmic reticulum. Our data showed that proteins that were not co-expressed in 
HEK-293 cells and did not undergo ER processing together do not oligomerize as 
evidenced by Ne+ affinity chromatography. Co-immunoprecipitation ofHIS-WT-SERT 
+ HA-I425V-SERT in the co-transfected conditioned revealed that I425V is not a signal 
for ER retention and is processed normally in the ER, while appearing to decrease total 
SERT oligomerization compared to wild-type controls. Oligomerization has been 
proposed in the ER as a mechanism for masking ER signal retention motifs within protein 
monomers (Standley, Roche et al. 2000). Mutations within GAT-! at the leucine zipper 
in TM2 results in proteins that are retained in the ER, however'! these mutants can still 
perform uptake of GABA showing that they are correctly folded (Scholze, Freissmuth et 
al. 2002). While we did not test uptake of 5-HT by wild-type and mutant I425V SERT in 
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these experiments as this has been previously performed, our results showed that co-
expression is necessary for SERT oligomerization. Also this data is supported in research 
pertaining to G-protein couple receptors (GPCRs). The ER has been viewed as a quality 
control mechanism for GPCRs in that monomer units of certain GPCRs. For example, 
the metabotropic GABAB receptor. This receptor is made up of two subunits GbR1 and 
GbR2. When GbR1 is expressed alone a signal sequence present in the C-terminal that is 
coded for an ER retention signal causes retention of the subunit within the ER. 
Oligomerization in the ER of GbRl with GbR2 causes the masking of the signal sequence 
and the receptor is properly exported from the ER (Terrillon and Bouvier 2004). 
However it is possible that oligomerization of GPCRs can also be regulated on the 
plasma membrane and not just in the ER. Several studies have shown that ligand binding 
can either promote (Rodriguez-Frade, Vila-Coro et al. 1999; Angers, Salahpour et al. 
2000) or inhibit (Gines 2000; Cheng and Miller 2001) GPCR oligomerization. However, 
it is relatively unknown if phosphorylation of GPCRs affects their oligomerization state. 
Therefore while earlier studies have focused on the importance of oligomerization for ER 
exportation we have showed the oligomerization is also necessary for functional 
regulation of SER T. It is important in the future to also look at other proteins that 
oligomerize and how they are affected by protein-kinase signaling cascades. The result 
of this nlay allow researchers to possibly draw a common conclusion about the regulation 
and effect of oligomerization in both receptors and transporters. 
Lastly we chose to look at the effects of cocaine on SERT oligomerization. We 
applied a range of cocaine concentrations [0-50 ~M] to HEK-293 cells transfected with 
HIS-WT-SERT + HA-WT-SERT for 30 minutes at 37°C. We saw a significant increase 
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in SERT oligomerization at the 7.5 11M cocaine concentration, which appears to be a 
physiologically relevant cocaine dose (Peter Kalivas, Personal Communication) and has 
been used in other studies studying cellular cocaine effects (Zhu MY et aI, 2000; Daws 
LC et aI, 2002). Concentrations higher and lower than 7.5 11M did not show significant 
increases in SER T oligomerization, but did show a trend of decreased oligomerization in 
higher concentrations which are most likely due to problems with cell toxicity. Cocaine 
is a drug that targets the monoamine transporters: SER T, DA T, and NET, with a high 
affinity for SERT and DA T. It acts as a reuptake inhibitor in that it binds to these 
transporters and blocks transporter-mediated reuptake of transmitter molecules from the 
synapse. This in tum can elevate extracellular transmitter concentrations and cause a 
wide variety of effects including paranoid ideation and psychosis (Gawin and Kleber 
1986). Chang and colleagues have showed that cocaine-binding occurs with equal 
affinity to SERT monomers, dimers, trimers, and tetramers, while only monomers, 
dimers, and tetramers revealed significant 5-HT uptake (Chang et al 1998). Therefore it 
is feasible that cocaine can bind to any possible oligomeric state of SERT and possibly 
have an effect on its oligomerization. Another study in DAT found that DAT expression 
in irradiated striatal membrane preparations was proposed to be a homo- or hetero-
oligomer when occupied in situ by uptake-blocking drugs such as cocaine (Berger SP et 
al 1994). Support from receptor studies helps show that cocaine may indeed induce 
increase in protein oligomerization. An example of this was a study by Xi et al 2002 that 
showed treatment of rats with injected cocaine daily after extinction for 1 and 3 weeks 
showed elevations of the mGluR2/3 dimer in the nucleus accumbens and the prefrontal 
cortex (PFC) with a reduction in the monomer in PFC only (XI, Ramamoorthy et al. 
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2002). Also as previously mentioned, studies have shown that oligomerization of GPCRs 
is increased due to ligand binding (Rodriguez-Frade, Vila-Coro et al. 1999; Angers, 
Salahpour et al. 2000). It is possible that one of cocaine's modes of function is to 
decrease monoamine uptake by increasing oligomerization instead of blocking the 
translo'cation pore. Acute cocaine administration has been shown to increase DAT 
(Zahniser and Sorkin 2004) surface expression which is in direct contrast to PKC-
mediated decreases in SERT plasma membrane expression (Ramamoorthy, Giovanetti et 
al. 1998). Research on cocaine's effect on cGMP levels has been debated. For example 
it has been found to decrease levels of cGMP in that rat ventral tagmental area upon 
injection (Jouvert P et ai, 2004) but it has been shown to increase intracellular cGMP 
concentrations in other rat brain structures (Macedo DS et ai, 2001) and heterologous cell 
systems (Yang Y et ai, 2001). However these latter studies were conducted in rat 
prefrontal cortex and through muscarinic receptors in HEL299 cells, respectively. 
Therefore, it is possible that cocaine may have exert different effects on cGMP levels 
depending on the brain area or cell system that is used. It is possible that while both 
(cocaine, and PKC) increase SERT oligomerization that they cause SERT to undergo 
different trafficking pathways with respect to surface expression. 
While in our experiments both p .. PMA (for PKC activation) and cocaine were pre .. 
incubated with HEK .. 293 cells for 30 minutes at 37°C. These two, PKC and cocaine, have 
been predicted to bind at different sites within the transporter. While the PKC binding 
site is unknown it is thought to be an internal site within SERT (Ramamoorthy, Bauman 
et al. 1993). The cocaine binding site is exposed to the extracellular milieu and thought 
to be a separate binding site then the anti-depressant extracellular binding site, both of 
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which are under location speculation (Rothman RB, 1999b). However it is speculated 
that both PKC and cocaine bind multiple sites within SERT and therefore it is difficult to 
state which sites are responsible for oligomerization and/or internalization. It is 
interesting though that administration of drugs of abuse that are substrates for SERT (e.g. 
amphetamine and methylphenidate) have been shown to increase transporter 
internalization, in direct contrast of cocaine's effect of increasing transporter plasma 
membrane expression (Boot, Meehan et al. 2002; Xie, Tong et al. 2006). They have also 
been found to both be activators ofPKC.(Kramer, Poblete et al. 1997; Hsieh, Yang et al. 
2005; Xie and Miller 2007) allowing a connection to be made between the effects of 
amphetamine and PKC, both of which cause an internalization ofSERT. Also, PKC 
activation or ampthetamine treatment ofHEK-293 cells transiently and stably transfected 
with DA T showed increases in FRET signaling in endosomes, indicative of efficient 
oligomerization of internalized DAT (Sorkina, Doolen et al. 2003). It is also possible 
that cocaine may exert its effect on protein kinases that in tum may affect SER T 
oligomerization, because cocaine's principal target is the SER T protein itself this may not 
be feasible. Therefore it is possible that these two processes, PKC activation and cocaine 
binding, while both causing increases in oligomerization, due to different sites of 
interaction may cause differing alterations in SER T trafficking. 
Taken together the present data show that phosphorylation of SERT or mutations 
within SERT have a profound effect on SERT oligomerization. While we cannot 
definitely say that a gain or loss of quaternary structure in oligomerization causes 
changes in SERT uptake, we can state that for the first time that kinases that have been 
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shown to increase SERT uptake of 5-HT (PKG and p38 MAPK) decrease SERT 
oligomerization and a kinase that has been shown to decrease 5-HT uptake (PKC) results 
in an increase in SERT oligomerization. Other studies performed have looked at mainly 
mutational methods to show that SERT exists as an oligomer but this is the first time that 
SER T oligomerization has been found to be a consequence of protein kinase-protein 
association with SERT. While our findings shed some light into the process ofSERT 
oligomerization several questions still remain to be asked. First, where does 
oligomerization occur in the cell? It has been hypothesized that oligomerization occurs 
in the ER during the folding process and is necessary for plasma membrane insertion 
(Farhan, Reiterer et al. 2007). However there has been no data reported that speaks to 
affecting oligomerization of SER T outside of the ER even though it has been thought to 
be necessary for ER export. Are there other kinases or inhibition of phosphatases that 
possibly could cause changes in SERT oligomerization? For example, PP1/PP2A 
inhibitors such as okadaic acid have been found to decrease SERT activity with 
concomitant down-regulation ofSERT (Ramamoorthy, Giovanetti et al. 1998; Bauman, 
Apparsundaram et al. 2000; Bauman, Apparsundaram et al. 2000). Also kinases such as 
protein kinase A (PKA) (Ramamoorthy, Ramamoorthy et al. 1995), and Calmodulin-
Dependent Kinase II (CamKII) (Jayanthi, Ramamoorthy et al. 1994), have been found to 
have effects on SERT activity and gene expression as well. What are the effects of 
chronically activated kinases such as PKA on SERT oligomerization? Lastly, what role 
does 1425V's and G56A;s effect on oligomerization play in human disease? Overall, this 
study opens new doors for future transporter research. With recent crystalizing of the 
Leur bacterial homologue transporter (Yamashita, Singh et al. 2005) and subsequent 
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follow-up papers (Beuming, Shi et al. 2006; Ravna, Jaronczyk et al. 2006), we now have 
a greater understanding of the three-dimensional topography of SERT. With this 
knowledge we can probe into the underpinnings that regulate oligomerization and 
identify not only the sites but also the mechanisms underlying this dynamic process. 
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